<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disorders of fibrinogen</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disorders of fibrinogen</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disorders of fibrinogen</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alessandro Casini, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caroline Bérubé, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fibrinogen plays a pivotal role in hemostasis and host defense and facilitates wound healing. </p><p>Fibrinogen disorders can have both hemorrhagic and thrombotic manifestations, as well as effects on pregnancy.</p><p>This topic describes the pathophysiology, clinical presentation, diagnosis, and treatment of inherited and acquired fibrinogen disorders.</p><p>Separate topic reviews discuss other bleeding disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemophilia – (See  <a class="medical medical_review" href="/d/html/1310.html" rel="external">"Clinical manifestations and diagnosis of hemophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Less-common hereditary coagulation factor deficiencies – (See  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a> and  <a class="medical medical_review" href="/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired factor inhibitors – (See  <a class="medical medical_review" href="/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease – (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated intravascular coagulation (DIC) – (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained bleeding – (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of<strong> </strong>fibrinolysis – (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis"</a>.)</p><p></p><p class="headingAnchor" id="H3859298806"><span class="h1">BIOLOGY</span></p><p class="headingAnchor" id="H717012142"><span class="h2">Fibrinogen synthesis and circulating levels</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structure</strong> – Fibrinogen (coagulation factor I; FG; FBG) is a 340 kD hexameric glycoprotein (GP) composed of two symmetrical halves that are centrally connected by three disulfide bonds  (<a class="graphic graphic_figure graphicRef68948" href="/d/graphic/68948.html" rel="external">figure 1</a>). Each half of the protein consists of three polypeptide chains (ie, A-alpha [Aα], B-beta [Bβ], and gamma [γ]) encoded by three different genes on chromosome 4 (<em>FGA</em>, <em>FGB</em>, and <em>FGG</em>). The nomenclature Aα and Bβ come from the designation of the small fibrinopeptides A (FpA) and B (FpB), which are cleaved by thrombin leading to the α and β chains without fibrinopeptides [<a href="#rid1">1</a>]. (See <a class="local">'Formation of fibrin'</a> below.)</p><p></p><p class="bulletIndent1">The trinodular structure of fibrinogen can be described as a central E region (containing the amino-terminal [N-terminal] portions of the three polypeptide chains) and two D regions (C-terminal portions) [<a href="#rid1">1</a>]. The fully assembled hexamer can be designated (AαB<sub>β</sub>γ)<sub>2</sub> [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Polymorphisms have been described in <em>FGA</em> and <em>FGB</em>, the Aα and Bβ gene, respectively. They are associated with abnormal fibrin clot structure, leading to hypofibrinolysis, defective factor XIII-dependent fibrin cross-linking, and increased plasma fibrinogen concentration, especially in smokers [<a href="#rid3">3,4</a>]. (See <a class="local">'Acquired hyperfibrinogenemia'</a> below.)</p><p></p><p class="bulletIndent1">Alternative splicing produces a normally occurring variant of the γ chain, which is referred to as "gamma-prime" (γ'). This yields γ' fibrinogen when assembled into the fibrinogen molecule [<a href="#rid5">5-8</a>]. This variant, which constitutes approximately 8 to 15 percent of plasma fibrinogen, is associated with structural changes in fibrin clots that include more extensive crosslinking and greater resistance to lysis. Another alternative splicing gives rise to a longer Aα chain (αE) in one to two percent of fibrinogen molecules [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Synthesis</strong> – Fibrinogen is produced primarily in the liver. All three polypeptides (Aα, Bβ, and γ) are synthesized by hepatocytes and assembled in a stepwise manner in the liver [<a href="#rid10">10,11</a>]. Carbohydrate side chains are added to the β and γ chains before the molecule is secreted into the circulation. Synthesis is controlled at the level of transcription. Extra-hepatic synthesis occurs in the trophoblast and in epithelial cells of the lung [<a href="#rid12">12,13</a>]. </p><p></p><p class="bulletIndent1">There is an inflammation-induced increase in fibrinogen, mainly due to the acute phase response. As an acute phase reactant, fibrinogen is increased by interleukin-6 (IL-6)-mediated increases in transcription. The acute phase response can elevate fibrinogen 2- to 20-fold, with a peak elevation by three to five days and a gradual return to baseline following resolution of the inflammatory stimulus [<a href="#rid14">14-16</a>]. IL-1 and tumor necrosis factor-alpha suppress fibrinogen synthesis [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/7483.html" rel="external">"Acute phase reactants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concentration</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plasma</strong> – As with all clotting factors, fibrinogen is present in plasma but not serum. It circulates at a concentration of approximately 200 to 400 mg/dL, by far the highest concentration of any coagulation factor [<a href="#rid17">17</a>]. This is because fibrinogen contributes a major structural component of the clot rather than an enzymatic function. </p><p></p><p class="bulletIndent2">The half-life of fibrinogen is approximately three to four days, with a catabolic rate of approximately 25 percent per day [<a href="#rid18">18</a>]. The fibrinogen catabolic pathway is mostly undetermined. </p><p></p><p class="bulletIndent2">Circulating plasma fibrinogen levels increase with age, obesity, smoking, and inflammatory states; levels decrease with alcohol consumption [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelets</strong> – The origin of platelet fibrinogen is controversial, as fibrinogen from platelets is structurally distinct from plasma fibrinogen [<a href="#rid20">20,21</a>]. A small pool of fibrinogen is principally taken up by platelets in a process mediated by platelet receptor GPIIb/IIIa and stored in platelet alpha-granules; this fibrinogen can support platelet aggregation. (See  <a class="medical medical_review" href="/d/html/6672.html" rel="external">"Megakaryocyte biology and platelet production", section on 'Granules'</a>.)</p><p></p><p class="headingAnchor" id="H3339706283"><span class="h2">Functions in hemostasis and other processes</span><span class="headingEndMark"> — </span>Fibrinogen has numerous functional interactions and plays a pivotal role in hemostatic balance. </p><p class="headingAnchor" id="H674236065"><span class="h3">Formation of fibrin</span><span class="headingEndMark"> — </span>Fibrinogen is the soluble precursor to fibrin, an insoluble protein that provides the major structural element of the clot. The conversion of fibrinogen into insoluble fibrin can be divided into three distinct steps:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinopeptide cleavage</strong> – Thrombin (factor IIa) is generated from prothrombin. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Thrombin generation'</a>.)</p><p></p><p class="bulletIndent1">When thrombin binds to fibrinogen, it cleaves FpA and FpB from the N-terminal portions of the Aα and Bβ chains at the Arg16-Gly17 and the Arg14-Gly15 bonds, respectively  (<a class="graphic graphic_figure graphicRef68948" href="/d/graphic/68948.html" rel="external">figure 1</a>). The resultant molecule is referred to as fibrin monomer, which is the basic unit of fibrin and facilitates optimal fibrin polymerization. FpA is released faster and earlier than FpB. FpA release is sufficient to induce clot formation, whereas isolated cleavage of FpB is insufficient. However, some homozygous fibrinogen variants with a defect in FpA release are still able to polymerize via B-b interactions [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1">Structural defects of the N-terminal regions of the Aα and Bβ chains can markedly impair thrombin binding, FpA or FpB release, and/or the rate of fibrin formation [<a href="#rid23">23</a>]. It is not surprising that many abnormal fibrinogens have mutations involving this region. However, the majority of the affected individuals are asymptomatic, although some have excessive bleeding, especially after surgery or childbirth. (See <a class="local">'Clinical manifestations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrin polymerization</strong> – In hemostasis, release of negatively charged FpA and FpB causes spontaneous fibrin monomer polymerization to form the clot. The figure shows a scanning electron micrograph image of polymerized fibrin  (<a class="graphic graphic_figure graphicRef142944" href="/d/graphic/142944.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1">Polymerization sites are located at the N-terminus of the Aα and Bβ chains (E domain) and the C-terminus of the γ chains (D domain). The process is initiated by complementary noncovalent binding of the polymerization sites through knob-hole interactions at the D region of one molecule to the central E domain of an adjacent fibrin monomer  (<a class="graphic graphic_figure graphicRef68948" href="/d/graphic/68948.html" rel="external">figure 1</a>), forming a two-molecule-thick strand or protofibril. This is followed by longitudinal growth (D-D contact between adjacent fibrin monomers), lateral aggregation of protofibrils, and branching to form the fibrin network  (<a class="graphic graphic_figure graphicRef62012" href="/d/graphic/62012.html" rel="external">figure 3</a>) [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">Pathogenic gene variants affecting these binding sites may delay fibrin polymerization and produce heterogeneous clinical manifestations. (See <a class="local">'Clinical manifestations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrin crosslinking</strong> – Once polymerized, fibrin is crosslinked. This final step strengthens the clot against mechanical and enzymatic disruption. Crosslinking is mediated by activated factor XIII (FXIIIa), which binds fibrin and generates covalent bonds between D domains of the fibrin fibers  (<a class="graphic graphic_figure graphicRef62012" href="/d/graphic/62012.html" rel="external">figure 3</a>). These bonds involve γ-γ as well as α-α (alpha C region domain) and α-γ chain interactions [<a href="#rid11">11,25,26</a>].</p><p></p><p class="bulletIndent1">Crosslinking stabilizes the clot and renders it resistant to disruption. Defective crosslinking due to an abnormal fibrinogen molecule may affect the mechanical resistance of the clot and be responsible for delayed wound healing and/or wound dehiscence, similar to that seen in patients with factor XIII deficiency. (See  <a class="medical medical_review" href="/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Factor XIII deficiency (F13D)'</a>.)</p><p></p><p class="bulletIndent1">It has been proposed that increased crosslinking might predispose to cardiovascular disease [<a href="#rid27">27,28</a>]. Clots containing γ' fibrinogen may have greater crosslinking (see <a class="local">'Fibrinogen synthesis and circulating levels'</a> above), and observational studies have found higher circulating levels of γ' fibrinogen (independent of circulating fibrinogen levels) in individuals with cardiac disease [<a href="#rid29">29,30</a>]. However, there is no evidence of a clinically significant causative role. On the contrary, in a murine model, elimination of fibrin γ-chain crosslinking increased pulmonary emboli, suggesting that fibrin γ-chain crosslinking may be essential for clot stability and could reduce the risk of clot embolization [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H3941002902"><span class="h3">Platelet aggregation</span><span class="headingEndMark"> — </span>Fibrinogen binds platelets and facilitates platelet aggregation, although platelet aggregation may also occur in the absence of fibrinogen (eg, via von Willebrand factor [VWF]). The binding of fibrinogen to platelets to support platelet aggregation is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Platelet aggregation'</a>.)</p><p class="headingAnchor" id="H190585824"><span class="h3">Fibrinolysis</span><span class="headingEndMark"> — </span>The fibrin clot is a template for the assembly and activation of the fibrinolytic system; it includes binding sites for plasminogen, tissue-type plasminogen activator (t-PA), and α-2-antiplasmin. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clot dissolution and fibrinolysis'</a>.)</p><p>Mutations affecting these binding regions may impair plasmin generation and reduce fibrinolysis [<a href="#rid32">32</a>]. The rate of fibrinolysis is also influenced by the thickness of the fibers [<a href="#rid33">33</a>]. Resistance to plasmin can result from mutations in the C-terminus of the Aα chain associated with abnormal albumin binding [<a href="#rid34">34-36</a>]. These mechanisms explain the thrombophilic phenotype in some individuals. (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'Overview of the fibrinolytic system'</a>.)</p><p>The locations have been mapped for certain amino acid residues that define the sites of some of the important functions of fibrinogen, including fibrinopeptide cleavage, fibrin polymerization, and factor XIIIa-mediated fibrin crosslinking as well as its interaction with platelet GPIIb/IIIa [<a href="#rid32">32,37-39</a>]. (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Overview of platelet function'</a>.)</p><p>Fibrin has thrombin-neutralizing activity, and it has been proposed that severe fibrinogen deficiency or dysfibrinogenemia might increase thrombosis risk because thrombin activity is generated at a normal rate, but neutralization is decreased (although further study is needed) [<a href="#rid40">40</a>]. Reduced antithrombin activity and increased thrombin generation with platelet activation and VWF-mediated platelet aggregation may occur in some individuals [<a href="#rid2">2,41,42</a>]. </p><p>Resistance to fibrinolysis may contribute to some thrombotic phenotypes such as chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism. In a small study involving 33 patients with CTEPH, five were found to have dysfibrinogenemia [<a href="#rid43">43</a>]. However, among dysfibrinogenemia variants described in this cohort, two appear not to be pathogenic variants, and one is usually identified in hypofibrinogenemia with fibrinogen storage disease; as a result, a clear link between CTEPH and dysfibrinogenemia is debated. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H998318554"><span class="h3">Wound healing</span><span class="headingEndMark"> — </span>Fibrinogen is involved in other physiologic processes including wound healing and inflammatory and immune responses [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/15080.html" rel="external">"Basic principles of wound healing", section on 'Epithelialization'</a> and  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Integration into other systems'</a>.)</p><p class="headingAnchor" id="H1241217950"><span class="h3">Placental insertion</span><span class="headingEndMark"> — </span>During pregnancy, fibrinogen plays a fundamental role in maintaining the integrity of placental insertion. In a mouse model of homozygous, Aα chain deficiency, fatal uterine bleeding occurs at approximately the tenth day of gestation [<a href="#rid45">45</a>]. </p><p>Some patients with congenital fibrinogen disorders have an increased risk of pregnancy loss, obstetric bleeding, or thrombosis during pregnancy or postpartum. (See <a class="local">'Obstetric complications'</a> below.)</p><p class="headingAnchor" id="H2490206628"><span class="h2">Types of fibrinogen abnormalities</span><span class="headingEndMark"> — </span>Disorders of fibrinogen can be inherited or acquired and can involve abnormalities in the amount of fibrinogen (quantitative defect), abnormalities in the function of the fibrinogen molecule (qualitative defect), or both  (<a class="graphic graphic_table graphicRef55144" href="/d/graphic/55144.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Afibrinogenemia</strong> – Absence of circulating fibrinogen due to a rare inherited autosomal recessive condition. Afibrinogenemia may be associated with bleeding, obstetric complications, and (rarely) thrombosis. (See <a class="local">'Congenital afibrinogenemia or hypofibrinogenemia'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypofibrinogenemia</strong> – Reduced level of circulating fibrinogen to below the lower end of the normal range. As discussed below, the threshold for clinical bleeding is &lt;100 mg/dL (see <a class="local">'Bleeding and abnormal clotting times'</a> below). Hypofibrinogenemia can be inherited or acquired (due to decreased synthesis or increased turnover [consumption]). Some individuals have phenotypes similar to afibrinogenemia; many affected individuals are asymptomatic. (See <a class="local">'Congenital afibrinogenemia or hypofibrinogenemia'</a> below and <a class="local">'Acquired hypo- or dysfibrinogenemia'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperfibrinogenemia</strong> – Increased level of circulating fibrinogen (eg, &gt;450 mg/dL). Hyperfibrinogenemia is typically a transient, acquired finding that occurs in the setting of acute inflammation or injury (as an acute phase process) and often is observed as an incidental finding; routine testing for hyperfibrinogenemia is not advised. (See <a class="local">'Acquired hyperfibrinogenemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Qualitative disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysfibrinogenemia</strong> – Presence of a dysfunctional fibrinogen molecule. Dysfibrinogenemia can be inherited or acquired (eg, in liver disease). Dysfibrinogenemias can be associated with bleeding, thrombosis, or both. (See <a class="local">'Congenital dysfibrinogenemia or hypodysfibrinogenemia'</a> below and <a class="local">'Acquired hypo- or dysfibrinogenemia'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypodysfibrinogenemia</strong> – Reduced fibrinogen that is also functionally abnormal. Hypodysfibrinogenemia can be inherited or acquired and can be associated with bleeding, thrombosis, or both.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cryofibrinogenemia</strong> – Cryofibrinogenemia is an acquired condition in which circulating fibrinogen, fibrin, fibronectin, and other plasma proteins precipitate at low temperatures  (<a class="graphic graphic_figure graphicRef142943" href="/d/graphic/142943.html" rel="external">figure 4</a>). Cryofibrinogenemia can be asymptomatic (incidental finding in a healthy person) or associated with cutaneous or rheumatologic manifestations such as cold sensitivity, purpura, skin necrosis, or Raynaud phenomenon. (See <a class="local">'Cryofibrinogenemia'</a> below.)</p><p></p><p class="headingAnchor" id="H2649388011"><span class="h1">HERITABLE (GENETIC) DISORDERS</span><span class="headingEndMark"> — </span>Heritable fibrinogen disorders include quantitative disorders (afibrinogenemia and hypofibrinogenemia), qualitative disorders (dysfibrinogenemia), and combined disorders (hypodysfibrinogenemia) [<a href="#rid46">46,47</a>]. (See <a class="local">'Types of fibrinogen abnormalities'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Databases </strong>– International databases that include all the identified variants in fibrinogen genes are available online. These include the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsite.geht.org%2Fbase-de-donnees-fibrinogene%2F&amp;token=A5bwtelKrYfyQf4yZVU1eHJIX1Pzt4YWoXYp3OxH%2Bmf49u3ewnXgoMH%2BkidunoFbAYLedFQq2u0475wlPA0SBw%3D%3D&amp;TOPIC_ID=1321" target="_blank">Human fibrinogen database</a> and the Human Gene Mutation database (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hgmd.cf.ac.uk%2Fac%2Findex.php&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2Zycaw1a%2Brkk7qfe9MeRA2pHRT3vXemQIsMIujEloHJt&amp;TOPIC_ID=1321" target="_blank">HGMD</a>) [<a href="#rid48">48</a>]. Variants have been summarized and updated in various review articles and are illustrated in the figure  (<a class="graphic graphic_figure graphicRef123075" href="/d/graphic/123075.html" rel="external">figure 5</a>) [<a href="#rid2">2,47,49-52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – These disorders are rare, although some individuals remain undiagnosed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>According to a 2014 global survey of rare bleeding disorders, severe inherited fibrinogen deficiencies accounted for 1712 of 283,397 inherited bleeding disorders (0.6 percent of the total; 8 percent of rare coagulation disorders), which is approximately as common as factor V or factor X deficiency and approximately 100 times less common than hemophilia A [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Support for a higher prevalence comes from reports that have found more than 50 percent of individuals with fibrinogen variants are asymptomatic and identified incidentally or through familial screening [<a href="#rid54">54-56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype-phenotype correlation</strong> – Bleeding can correlate with the fibrinogen level, but it is not always possible to predict the genotype-phenotype relationship in the congenital dysfibrinogenemias, making it difficult to anticipate whether a specific variant is more likely to cause bleeding, thrombosis, both, or neither [<a href="#rid54">54,57</a>]. Structural analysis has been used to correlate specific variants with specific alterations of protein function [<a href="#rid32">32,38,58</a>]. </p><p></p><p class="headingAnchor" id="H1392080744"><span class="h2">Congenital afibrinogenemia or hypofibrinogenemia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Afibrinogenemia</strong> – Congenital afibrinogenemia is an extremely rare (estimated incidence one per million), autosomal recessive condition due to homozygosity or compound heterozygosity for null mutations in one of the fibrinogen genes (mainly <em>FGA</em>) [<a href="#rid2">2,52,59-62</a>]. Consanguinity may play a role in some kindreds. </p><p></p><p class="bulletIndent1">A number of variants in<em> FGA</em> and other fibrinogen genes have been identified  (<a class="graphic graphic_figure graphicRef123075" href="/d/graphic/123075.html" rel="external">figure 5</a>); these may affect mRNA splicing or stability; protein production or stability; or hexamer assembly, storage, or secretion [<a href="#rid60">60</a>]. In a large 2021 case series, most variants were in<em> FGA</em>, common variants included an 11 kilobase deletion, the frameshift mutation c.510+1T&gt;G, and a nonsense mutation c.635T&gt;G [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypofibrinogenemia</strong> – Congenital hypofibrinogenemia (fibrinogen or below the lower limit of normal range, typically &lt;150 mg/dL [&lt;1.5 g/L]) is often seen in heterozygous carriers of afibrinogenemia mutations [<a href="#rid2">2,60,64-66</a>]. A classification of congenital fibrinogen disorders published in 2018 defines hypofibrinogenemia as any value below the reference range [<a href="#rid67">67</a>]. Congenital hypofibrinogenemia is more prevalent than afibrinogenemia, but the true incidence is unknown since many cases are asymptomatic and never come to medical attention [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">Plasma fibrinogen levels of ≥100 mg/dL are often sufficient to prevent spontaneous bleeding, and affected individuals often do not come to medical attention. However, bleeding, pregnancy loss, or liver disease may occur with surgery, trauma, or pregnancy. Bleeding risk is likely to increase as the fibrinogen level decreases to &lt;100 mg/dL. (See <a class="local">'Bleeding and abnormal clotting times'</a> below.)</p><p></p><p class="headingAnchor" id="H16451060"><span class="h2">Congenital dysfibrinogenemia or hypodysfibrinogenemia</span><span class="headingEndMark"> — </span>Congenital fibrinogen variants that affect fibrinogen function can be categorized as dysfibrinogenemia (normal levels of dysfunctional fibrinogen) or hypodysfibrinogenemia (dysfunctional fibrinogen at low plasma concentration). In both cases, the fibrinogen antigen level does not reflect the level of functional fibrinogen, which must be measured using a functional assay. (See <a class="local">'Diagnostic testing'</a> below.)</p><p>Transmission of dysfibrinogenemias (and hypodysfibrinogenemias) is autosomal dominant, mainly caused by heterozygosity for a missense mutation in the coding region of one of the fibrinogen genes that leads to production of an abnormal fibrinogen protein [<a href="#rid47">47</a>]. Abnormalities may involve alteration of fibrinopeptide release, fibrin polymerization, fibrin crosslinking, or fibrinolysis. Congenital dysfibrinogenemia is quite rare but occurs more frequently than congenital afibrinogenemia; the true incidence is unknown since many cases are asymptomatic and never come to medical attention [<a href="#rid47">47</a>].</p><p>Examples of common sites of pathogenic variants ("hotspots"  (<a class="graphic graphic_figure graphicRef123075" href="/d/graphic/123075.html" rel="external">figure 5</a>)) and their functional effects include:</p><p class="bulletIndent1"><span class="glyph">●</span><em>FGA</em> exon 2 mutations that affect fibrinopeptide A (FPA) cleavage</p><p class="bulletIndent1"><span class="glyph">●</span><em>FGG</em> exon 8 mutations that affect the fibrin polymerization site</p><p></p><p>In a 2015 study that included 101 patients with inherited dysfibrinogenemia, mutations at the <em>FGA</em> hotspot accounted for 24 percent and variants at the <em>FGG</em> hotspot accounted for 51 percent of all mutations [<a href="#rid54">54</a>]. The cumulative incidences of major bleeding and thrombosis at age 50 years were 19 and 30 percent, respectively [<a href="#rid54">54</a>]. Certain mutations may be associated with both bleeding and thrombosis (see <a class="local">'Clinical manifestations'</a> below). In this same cohort of 101 patients, no association could be established between the common hotspot mutations and clinical phenotype of bleeding or thrombosis [<a href="#rid54">54</a>].</p><p>As for afibrinogenemia and hypofibrinogenemia variants, inherited dysfibrinogenemias are named after the city where the patient was first identified or evaluated. Roman numerals are added after the city name when there are several dysfibrinogens from the same city (eg, Caracas V).</p><p class="headingAnchor" id="H19"><span class="h1">ACQUIRED ABNORMALITIES</span></p><p class="headingAnchor" id="H20"><span class="h2">Acquired hypo- or dysfibrinogenemia</span><span class="headingEndMark"> — </span>Acquired fibrinogen disorders are more common than inherited disorders because liver disease and disseminated intravascular coagulation (DIC) are common  (<a class="graphic graphic_table graphicRef55144" href="/d/graphic/55144.html" rel="external">table 1</a>). Since fibrinogen is an acute phase reactant that normally increases in the setting of inflammation, it is possible that an apparently normal fibrinogen level in an individual with an inflammatory condition may actually represent a significant decline from the patient's baseline.</p><p class="headingAnchor" id="H21"><span class="h3">Liver disease</span><span class="headingEndMark"> — </span>Liver disease can cause dysfibrinogenemia and/or hypofibrinogenemia; the latter most often accompanies more severe liver disease and cirrhosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysfibrinogenemia</strong> – Liver disease is the most common cause of acquired dysfibrinogenemia, with prevalence as high as 80 percent if a highly sensitive assay is used [<a href="#rid68">68</a>]. Dysfibrinogenemia has been seen in biliary obstruction, acute liver failure, chronic liver disease, cirrhosis, and hepatoma [<a href="#rid68">68-73</a>]. The abnormal fibrinogen has an increased content of sialic acid residues that results in delayed fibrin aggregation [<a href="#rid74">74</a>]. Cleavage of the A and B fibrinopeptides and the crosslinking of fibrin by factor XIIIa are normal. Cleavage of sialic acid from the abnormal fibrinogen restored fibrinogen function to normal in vitro [<a href="#rid75">75</a>]. The impact of this abnormal fibrinogen has not been well studied, but it is unlikely to be associated with significant alteration of bleeding risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypofibrinogenemia</strong> – Liver disease can also reduce fibrinogen levels. Typically, this occurs with advanced liver disease severe enough to compromise liver synthetic function.</p><p></p><p>The impact of dysfibrinogenemia and hypofibrinogenemia on bleeding risk in individuals with liver disease is difficult to assess since liver disease produces numerous procoagulant and anticoagulant changes. Patient evaluation is presented separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p class="headingAnchor" id="H1713687949"><span class="h3">DIC</span><span class="headingEndMark"> — </span>Disseminated intravascular coagulation (DIC) is a consumptive coagulopathy that can cause hypofibrinogenemia and/or dysfibrinogenemia  (<a class="graphic graphic_figure graphicRef78959" href="/d/graphic/78959.html" rel="external">figure 6</a>). Increased fibrin degradation products in DIC also impair normal fibrinogen function. </p><p>Acute DIC is the most common cause of acquired hypofibrinogenemia. In chronic DIC, the fibrinogen may be normal or even increased. Patients with DIC and hypofibrinogenemia may have bleeding or thrombotic manifestations. Evaluation and management are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a>.)</p><p class="headingAnchor" id="H456840985"><span class="h3">Hemophagocytic lymphohistiocytosis</span><span class="headingEndMark"> — </span>Hemophagocytic lymphohistiocytosis (HLH) is an aggressive systemic disorder of excessive immune activation and multiorgan dysfunction. Hypofibrinogenemia is frequently seen (and is one of the syndromic criteria), often with liver enzyme abnormalities and prolonged coagulation times. The mechanism of hypofibrinogenemia is not well explained, especially since inflammation typically raises the fibrinogen level. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a> and <a class="local">'Fibrinogen synthesis and circulating levels'</a> above.)</p><p>Treatment of bleeding in HLH and the role of monitoring fibrinogen along with other disease markers are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p class="headingAnchor" id="H2980556620"><span class="h3">Antifibrinogen antibodies</span><span class="headingEndMark"> — </span>Autoantibodies that inhibit fibrinogen function have been described in various conditions. Examples include [<a href="#rid76">76-81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (SLE)</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis (RA)</p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerative colitis</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple myeloma</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial myopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>)</p><p></p><p>These antibodies may interfere with fibrinopeptide release, fibrin monomer polymerization, or fibrin crosslinking. In RA, the autoantibody is directed against citrullinated fibrinogen (in which arginine is post-translationally modified to citrulline). Additional details regarding this modification in RA are presented separately. (See  <a class="medical medical_review" href="/d/html/7513.html" rel="external">"Pathogenesis of rheumatoid arthritis", section on 'Citrullinated proteins and peptides'</a>.)</p><p>Autoantibodies are more likely to cause bleeding manifestations than thrombosis. In some cases, the autoantibody may be clinically silent. </p><p>Some individuals have no identifiable underlying disorder.</p><p>Patients exposed to fibrin glue during surgical procedures using a product prepared from bovine sources can develop alloantibodies against bovine fibrinogen that may cross-react with human fibrinogen [<a href="#rid82">82</a>]. Commercial fibrin sealants made from human sources (eg, Tisseel kit VH, Vistaseal, Evicel, Artiss) should eliminate this complication. (See  <a class="medical medical_review" href="/d/html/7938.html" rel="external">"Fibrin sealants", section on 'Formulations and use'</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Other causes (medications, paraneoplastic, plasma exchange)</span><span class="headingEndMark"> — </span>Acquired dysfibrinogenemia and hypofibrinogenemia have also been reported in association with other conditions  (<a class="graphic graphic_table graphicRef55144" href="/d/graphic/55144.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Renal carcinoma (possible paraneoplastic syndrome) [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple myeloma (impaired fibrin polymerization due to the paraprotein)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">Isotretinoin</a> therapy (in acute pancreatitis, mechanism unclear) [<a href="#rid84">84</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">Tigecycline</a> (mechanism unclear) [<a href="#rid85">85</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Medications that impair hepatic synthetic function (L-asparaginase, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>) [<a href="#rid86">86-88</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Trauma-induced coagulopathy [<a href="#rid89">89</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Acute obstetric coagulopathy during postpartum hemorrhage [<a href="#rid90">90</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma exchange using albumin as a replacement fluid</p><p></p><p>Following plasma exchange, the fibrinogen level may decrease by approximately 50 percent. In contrast, if plasma is used as a replacement fluid, changes in fibrinogen are negligible. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'Replacement fluids'</a>.)</p><p>As with the acquired systemic disorders discussed above, hypofibrinogenemia may be accompanied by other coagulation abnormalities. Primary fibrinolytic states leading to hypofibrinogenemia are rare. (See  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis"</a>.)</p><p>Increased fibrin split products (FSPs) or fibrin degradation products, which come from non-crosslinked fibrin, could impair optimal fibrin polymerization and the functional fibrinogen level. D-dimer, which comes from crosslinked fibrin, does not affect the fibrinogen assay.</p><p class="headingAnchor" id="H16450711"><span class="h2">Acquired hyperfibrinogenemia</span><span class="headingEndMark"> — </span>Increased fibrinogen (hyperfibrinogenemia) can be seen in inflammation or tissue injury as an acute phase reactant. Inherited hyperfibrinogenemia has not been reported, although certain genetic variants may increase fibrinogen levels in some settings, such as pregnancy or insulin resistance [<a href="#rid91">91,92</a>]. The clinical significance is uncertain.</p><p>Epidemiologic studies indicate that high fibrinogen is associated with increased risk of cardiovascular disease, stroke, and nonvascular mortality, but causality has not been demonstrated. (See  <a class="medical medical_review" href="/d/html/16307.html" rel="external">"Overview of possible risk factors for cardiovascular disease", section on 'Coagulation factors'</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">CRYOFIBRINOGENEMIA</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Cryofibrinogenemia refers to an abnormal cold insoluble protein in plasma (but not serum)  (<a class="graphic graphic_figure graphicRef142943" href="/d/graphic/142943.html" rel="external">figure 4</a>); the cryofibrinogen is composed of fibrinogen, fibrin, fibronectin, and other proteins [<a href="#rid93">93-95</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>– Cryofibrinogenemia is uncommon. Cryo<strong>globulins</strong> (cold insoluble proteins present in both serum and plasma) are more common; a study of 335 patient samples with measurable Cryoprecipitates found that 334 were cryoglobulins and only one was a cryofibrinogen [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia", section on 'Classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Rare heritable forms have been reported [<a href="#rid97">97-100</a>]. Most cryofibrinogenemia is secondary to an underlying disorder  (<a class="graphic graphic_table graphicRef72157" href="/d/graphic/72157.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune or connective tissue disorders or vasculitis [<a href="#rid101">101</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>Infection (hepatitis C virus, coronavirus disease 2019 [COVID-19]) [<a href="#rid102">102</a>]</p><p></p><p class="bulletIndent1">Low cryofibrinogen (&lt;50 mg/L) can also be present in individuals without an underlying condition [<a href="#rid103">103-106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – Some people with cryofibrinogenemia are asymptomatic. Others have clinical features of hyperviscosity, vascular reactivity, and/or thrombosis. Symptomatic individuals often have cryofibrinogen levels &gt;1 g/L. Signs and symptoms may include  (<a class="graphic graphic_table graphicRef102404" href="/d/graphic/102404.html" rel="external">table 3</a>) [<a href="#rid101">101,104-113</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cold sensitivity</p><p class="bulletIndent2"><span class="glyph">•</span>Raynaud phenomenon</p><p class="bulletIndent2"><span class="glyph">•</span>Painful ulcers or skin necrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Purpura</p><p class="bulletIndent2"><span class="glyph">•</span>Livedo reticularis</p><p class="bulletIndent2"><span class="glyph">•</span>Painful or pruritic erythema (perniosis) of the extremities</p><p class="bulletIndent2"><span class="glyph">•</span>Arthralgias</p><p class="bulletIndent2"><span class="glyph">•</span>Arterial thrombosis (stroke, myocardial infarction, limb or bowel ischemia, retinal artery occlusion, gangrene)</p><p class="bulletIndent2"><span class="glyph">•</span>Venous thromboembolism (VTE; pulmonary embolism, thrombophlebitis, retinal vein occlusion)</p><p></p><p class="bulletIndent1">A causal relationship with thromboembolism has not been established [<a href="#rid106">106,114,115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – The accuracy and sensitivity of the cryofibrinogen detection is critically dependent on the method of collection and sample handling. All samples should be drawn in a prewarmed (37ºC) tube, anticoagulated (with EDTA or citrate), and maintained at 37ºC until centrifuged, ideally with a temperature-controlled centrifuge. </p><p></p><p class="bulletIndent1">After separation, the plasma is refrigerated at 4ºC for 72 hours to screen for a precipitate, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef142943" href="/d/graphic/142943.html" rel="external">figure 4</a>). If positive, the "cryocrit" is then quantified after additional centrifugation in a graduated tube. A cryocrit of ≥1 percent is considered abnormal. The precipitation is reversible when warmed at 37ºC<strong>. </strong>Heparin should not be used as the anticoagulant because it can bind to fibrinogen [<a href="#rid116">116-119</a>].</p><p></p><p class="bulletIndent1">If a causative disorder is not obvious, a thorough evaluation including age-appropriate cancer screening should be performed. </p><p></p><p>Diagnosis of cryofibrinogenemia is based on identification of cryofibrinogen in plasma, without cryoglobulins in serum, and one or more clinically compatible features. The differential diagnosis includes cutaneous, vascular, and thrombotic conditions: </p><p class="bulletIndent2"><span class="glyph">•</span>Frostbite</p><p class="bulletIndent2"><span class="glyph">•</span>Atherosclerotic peripheral vascular disease</p><p class="bulletIndent2"><span class="glyph">•</span>Atheroemboli or septic emboli</p><p class="bulletIndent2"><span class="glyph">•</span>Hypercoagulable states</p><p class="bulletIndent2"><span class="glyph">•</span>DIC, thrombotic thrombocytopenic purpura (TTP), or hemolytic uremic syndrome (HUS)</p><p class="bulletIndent2"><span class="glyph">•</span>Antiphospholipid syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Calciphylaxis (calcium deposition, as in end-stage kidney disease [ESKD]) (see  <a class="medical medical_review" href="/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Purple toes syndrome associated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous disorders (urticaria, livedo or livedoid vasculitis, neutrophilic dermatoses, lipodermatosclerosis, panniculitis, or perniosis [chilblains])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The most reliable treatment for cold-induced events is avoidance of cold and other environmental triggers. Avoidance of sympathomimetic agents (diet pills, decongestants, caffeine, tobacco smoke) seems prudent, but supporting evidence is lacking. The roles of biofeedback or other behavioral therapies are undefined.</p><p></p><p class="bulletIndent1">In lymphoproliferative or connective tissue disorders, cryofibrinogens may decrease with treatment of the underlying disorder; evidence for efficacy is limited to small series or case reports [<a href="#rid103">103,120-129</a>]. </p><p></p><p class="bulletIndent1">Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus a glucocorticoid has been advocated for nonsevere symptoms [<a href="#rid101">101</a>]. The role of anticoagulation in the absence of thrombosis is controversial [<a href="#rid103">103,112,122,130</a>]. Anticoagulation is appropriate for treatment of thrombosis or standard prophylaxis indications. For critical acute ischemia due to cryofibrinogenemia, thrombolytic therapy (<a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>) can be used [<a href="#rid112">112,131-136</a>]. (See <a class="local">'Treatment and prevention of thrombosis'</a> below.) </p><p></p><p class="headingAnchor" id="H1512105416"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4089240339"><span class="h2">Bleeding and abnormal clotting times</span><span class="headingEndMark"> — </span>Hypofibrinogenemia or dysfibrinogenemia can cause prolongation of the prothrombin time (PT), activated partial thromboplastin time (aPTT), and/or thrombin time (TT). The sensitivity of the PT and aPTT assays differ depending on the laboratory, and some individuals may have a normal aPTT despite fibrinogen as low as 50 mg/dL. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p>Mild hypofibrinogenemia (100 to 150 mg/dL) may not affect clotting times. Rare cases of dysfibrinogenemia have been reported in which the TT is normal [<a href="#rid47">47,137</a>]. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Clotting times'</a>.)</p><p>Bleeding can be mild or severe, with greater bleeding risk with afibrinogenemia or functional fibrinogen &lt;100 mg/dL  (<a class="graphic graphic_table graphicRef114456" href="/d/graphic/114456.html" rel="external">table 4</a>). Earlier age of onset is likely with more severe deficiency or functional impairment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital afibrinogenemia </strong>– In congenital afibrinogenemia (absent fibrinogen), bleeding often occurs in the neonatal period, typically at the umbilical stump or after circumcision [<a href="#rid138">138</a>]. One of the larger case series that included 204 individuals with congenital afibrinogenemia reported that one-third had at least one bleed per month and one-fourth had a history of intracerebral bleeding [<a href="#rid63">63</a>]. Other common sites of bleeding included muscle hematomas, hemarthroses, and perioperative bleeds. The average International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT) score (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbleedingscore.certe.nl%2F&amp;token=Nn2kz6P9LalXZBakWq4EFVy%2FtKzfMxWmVZgnncoM9zqnY8WwoOfYCEf5tSBri%2Fvl&amp;TOPIC_ID=1321" target="_blank">bleedingscore.certe.nl/</a>) was 14, consistent with a severe bleeding disorder. Many of these individuals also experienced thrombotic events. (See <a class="local">'Thrombosis'</a> below.)</p><p></p><p class="bulletIndent1">Another series of 58 children and adolescents with hereditary afibrinogenemia reported intracerebral bleeding in 31 percent; two-thirds were traumatic (eg, fall down stairs), and one teenager died [<a href="#rid139">139</a>]. After recovering, seven children (12 percent) started fibrinogen prophylaxis. </p><p></p><p class="bulletIndent1">Other reports have reported that umbilical cord bleeding, which can be fatal, is the initial presentation in approximately 60 to 85 percent of cases [<a href="#rid2">2,47</a>]. </p><p></p><p class="bulletIndent1">Some individuals with afibrinogenemia may have a later age of onset with bleeding in the skin, gastrointestinal tract, urinary tract, or central nervous system. Many females have heavy menstrual bleeding. Pregnancy-associated hemorrhage (antepartum or postpartum) may occur. Splenic rupture has been reported [<a href="#rid42">42,140</a>]. Thrombosis may occur, sometimes after fibrinogen replacement therapy (essentially by cryoprecipitates). (See <a class="local">'Treatment/prevention of bleeding'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital hypofibrinogenemia</strong> – In congenital hypofibrinogenemia (fibrinogen below the lower level of the reference range, typically &lt;150 mg/dL), the frequency and characteristics of bleeding are variable. In a series of 100 individuals with congenital hypofibrinogenemia, the median fibrinogen level was 6 mg/dL (range, 0 to 116 mg/dL) [<a href="#rid141">141</a>]. The annualized bleeding rate was approximately 5 to 7 per 1000 patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital dysfibrinogenemia</strong> – Congenital dysfibrinogenemia (or hypodysfibrinogenemia) presentations are heterogeneous. Dysfibrinogenemia with functional fibrinogen &lt;50 to 100 mg/dL has a higher frequency of bleeding complications. However, case series have reported that the majority of individuals do not present with bleeding. In fact, over one-half of individuals in various series have been asymptomatic and identified as an incidental finding or through familial screening [<a href="#rid54">54-56</a>]. </p><p></p><p class="bulletIndent1">In a cohort of 101 patients with congenital dysfibrinogenemia, thrombosis was more common than bleeding [<a href="#rid54">54</a>]. At age 50, cumulative incidence of major bleeding was 19 percent and thrombosis was 30 percent. Spontaneous abortion occurred in 20 percent and postpartum hemorrhage in 21 percent. </p><p></p><p class="bulletIndent1">In a systematic review of hypodysfibrinogenemia associated with bleeding, 476 bleeding events were reported in 317 individuals [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1">Most bleeding is mild (heavy menstrual bleeding, cutaneous bleeding, epistaxis), but it can be severe (operative and gastrointestinal bleeding). Other concerning sites of bleeding include intracerebral, retroperitoneal, joint/muscle, and obstetric. Notably, antepartum and postpartum hemorrhage were reported in individuals without bleeding manifestations outside pregnancy [<a href="#rid142">142</a>]. Spontaneous life-threatening bleeds are rare. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired disorders</strong> – Acquired fibrinogen disorders may have bleeding due to low fibrinogen levels and/or other hemostatic abnormalities such as thrombocytopenia and/or other factor deficiencies. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Bleeding and thrombosis'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H376818620"><span class="h2">Thrombosis</span><span class="headingEndMark"> — </span>Paradoxically, some fibrinogen disorders cause thrombotic phenotypes, despite the prominent role of fibrinogen in normal clotting and the expectation that fibrinogen disorders would cause increased bleeding  (<a class="graphic graphic_table graphicRef114456" href="/d/graphic/114456.html" rel="external">table 4</a>) [<a href="#rid2">2</a>]. Both afibrinogenemia and dysfibrinogenemia have been associated with thrombotic manifestations. </p><p class="bulletIndent2"><span class="glyph">•</span><strong>Afibrinogenemia</strong> – A 2016 systematic review identified 48 reports of thromboembolic complications in individuals with congenital afibrinogenemia, which included arterial and venous thromboembolism (VTE) in a variety of vascular sites [<a href="#rid41">41</a>]. The median age at the time of the first event was 31 years, and in some cases, there was a triggering event such as infection or trauma. Most were treated with fibrinogen replacement; some were also given an anticoagulant or an antiplatelet agent (see <a class="local">'Management'</a> below). Outcomes were mostly good, although a few required surgery (eg, to resect infarcted bowel). </p><p></p><p class="bulletIndent2">A series of 204 individuals with congenital afibrinogenemia reported that a thrombotic event had occurred in 18 percent, with 43 percent VTE, 30 percent arterial, and 27 percent combined arterial and VTE [<a href="#rid63">63</a>]. Recurrent thrombotic events occurred in 41 percent.</p><p></p><p class="bulletIndent2">Thrombosis in unusual sites is not uncommon. In a series of 20 young patients (mean age 14.1 years), six had experienced a thrombotic event in unusual sites, including one aortic thrombosis and five in the splanchnic venous territory [<a href="#rid143">143</a>]. These events did not occur after a fibrinogen infusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysfibrinogenemia</strong> – In a series of 101 individuals with congenital dysfibrinogenemias, there were 20 episodes of VTE and eight arterial thromboses (eg, stroke, myocardial infarction, mesenteric thrombosis) [<a href="#rid54">54</a>]. One of the events may have been associated with fibrinogen replacement therapy. The annualized thrombotic rate was 7.6 per 1000 patients, and the estimated cumulative incidence of thrombotic events at age 50 years was 30 percent (95% CI 20-44 percent). </p><p></p><p class="bulletIndent2">In a 1995 report from the International Society on Thrombosis and Haemostasis (ISTH) on 27 individuals with thrombotic dysfibrinogenemia variants, the mean age of first thrombosis was 27 years (range, 12 to 50 years) [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent2">The classification of congenital fibrinogen disorders published in 2018 includes a subcategory of thrombotic dysfibrinogenemia associated with a thrombotic fibrinogen variant [<a href="#rid67">67</a>]. These mutations interfere with fibrinolysis due to defective binding to tissue-plasminogen activator and/or plasminogen at critical sites on the (dys)fibrinogen. An abnormal clot structure may also delay or impair fibrinolysis.</p><p></p><p class="bulletIndent2">VTE is more common than arterial, but both can occur, sometimes in the same individual [<a href="#rid54">54,55,144</a>]. In some cases, treatments given for bleeding may contribute to thrombotic risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired fibrinogen disorders</strong> – Thrombosis may be due to dysfibrinogenemia or to other hemostatic abnormalities. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Bleeding and thrombosis'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Portal vein thrombosis (PVT)'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Venous thromboembolism (VTE)'</a>.)</p><p></p><p>Fibrinogen abnormalities constitute an extremely rare cause of thrombophilia overall (&lt;1 percent), and testing for dysfibrinogenemia is <strong>not</strong> a routine component of the thrombophilia evaluation unless there is a known family history of an inherited fibrinogen disorder [<a href="#rid2">2,55</a>]. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'</a>.)</p><p>Cardiovascular disease associated with hyperfibrinogenemia is discussed below. (See <a class="local">'Other rare manifestations'</a> below.)</p><p class="headingAnchor" id="H2154716329"><span class="h2">Obstetric complications</span><span class="headingEndMark"> — </span>Compared with controls, individuals with fibrinogen abnormalities have bleeding and thrombotic complications during pregnancy and postpartum and an increased risk of recurrent pregnancy loss and abruptio placentae  (<a class="graphic graphic_table graphicRef114456" href="/d/graphic/114456.html" rel="external">table 4</a>) [<a href="#rid55">55,145</a>]. </p><p>The role of fibrinogen appears to be in the integrity of placental insertion rather than in earlier stages such as fertilization or initial implantation (see <a class="local">'Functions in hemostasis and other processes'</a> above). Fibrinogen levels typically increase as the pregnancy progresses, along with other changes. (See  <a class="medical medical_review" href="/d/html/429.html" rel="external">"Maternal adaptations to pregnancy: Hematologic changes", section on 'Coagulation and fibrinolysis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Afibrinogenemia</strong> – The likelihood of successful pregnancy appears to correlate with the fibrinogen level [<a href="#rid47">47</a>]. In a series of 204 individuals with congenital afibrinogenemia, 85 percent of females had experienced at least one pregnancy loss [<a href="#rid63">63</a>]. When it occurs, the timing of pregnancy loss is typically at approximately five to eight weeks gestation if fibrinogen replacement therapy is not administered [<a href="#rid47">47</a>]. (See <a class="local">'Conception and pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypofibrinogenemia</strong> – Hypofibrinogenemia does not appear to increase the risk of miscarriage. In a series that included 149 pregnancies in individuals with hypofibrinogenemia, 106 (71 percent) resulted in live births, while early miscarriage was reported in 18 (12 percent) and intrauterine fetal death was reported in 2 (1 percent) [<a href="#rid146">146</a>]. Vaginal bleeding throughout the pregnancy was described in 7 pregnancies (5 percent). Retroplacental hematoma and postpartum hemorrhage were frequent (8 and 18 percent, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysfibrinogenemia</strong> – Similar results were observed in 232 pregnancies in women with dysfibrinogenemia [<a href="#rid146">146</a>]. The rate of live birth was 71 percent, similar to that of the French general population. Postpartum hemorrhages were reported in 36 pregnancies (21 percent).</p><p></p><p class="headingAnchor" id="H1561048202"><span class="h2">Other rare manifestations</span><span class="headingEndMark"> — </span>Case reports have described other clinical manifestations  (<a class="graphic graphic_table graphicRef114456" href="/d/graphic/114456.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal amyloidosis</strong> – Hereditary renal amyloidosis caused by deposition of a mutant fibrinogen α chain has been reported. Inheritance is autosomal dominant, and most of the affected individuals developed kidney failure [<a href="#rid147">147-154</a>]. Coagulation assays are not affected. A database of <em>FGA</em> gene mutations associated with hereditary amyloidosis is available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Famyloidosismutations.com%2F&amp;token=4lGw4t6QaYXwfNlhsNlXuzHwvyyBM5If70Z48Aht3xxCMIcvJ73aEzfpbWPvSadI&amp;TOPIC_ID=1321" target="_blank">Mutations in Hereditary Amyloidosis</a>. (See  <a class="medical medical_review" href="/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/3120.html" rel="external">"Renal amyloidosis", section on 'Hereditary renal amyloidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Hepatic storage disease caused by accumulation of an abnormal fibrinogen in the hepatocyte endoplasmic reticulum has been reported in individuals with variants affecting exons 8 and 9 of the fibrinogen γ gene (<em>FGG</em>) [<a href="#rid155">155</a>]. Severity of liver disease is variable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenic rupture</strong> – Splenic rupture was reported in 5 percent of individuals with congenital afibrinogenemia in one series [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone cysts</strong> – Painful bone cysts have been reported in congenital afibrinogenemia [<a href="#rid156">156</a>]. These appear to be rare and to predominantly affect the long bones of young individuals, possibly as a complication of bleeding. In a series of 204 individuals with congenital afibrinogenemia, painful bone cysts were reported in 18 percent [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal wound healing</strong> – Delayed wound healing and/or surgical wound dehiscence has been reported in individuals with inherited afibrinogenemia or inherited dysfibrinogenemia [<a href="#rid42">42,157,158</a>]. (See  <a class="medical medical_review" href="/d/html/15080.html" rel="external">"Basic principles of wound healing"</a> and  <a class="medical medical_review" href="/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – Elevated fibrinogen levels (hyperfibrinogenemia) can be seen in inflammatory states and cardiovascular disease (see <a class="local">'Fibrinogen synthesis and circulating levels'</a> above and <a class="local">'Acquired hyperfibrinogenemia'</a> above), although a causative relationship may not exist, and there do not appear to be management implications specifically related to fibrinogen levels. </p><p></p><p class="bulletIndent1">Fibrinogen acts as an antithrombin; thus, low fibrinogen levels can be prothrombotic. Dysfibrinogenemia can be associated with arterial thrombosis (see <a class="local">'Thrombosis'</a> above). The relationship between fibrinogen abnormalities and cardiovascular disease is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">DIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H6298531"><span class="h2">Initial evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect</strong> – A fibrinogen disorder may be suspected in an individual with unexplained bleeding, thrombosis, or pregnancy morbidity for whom other testing did not uncover a cause  (<a class="graphic graphic_algorithm graphicRef114258" href="/d/graphic/114258.html" rel="external">algorithm 1</a>). It may also come to attention in an asymptomatic individual with unexplained prolonged baseline prothrombin time (PT) or activated partial thromboplastin time (aPTT) or a known familial fibrinogen disorder. Testing for dysfibrinogenemia is often added as a second- or third-line evaluation for an individual with thrombosis after more common thrombophilias have been eliminated. Acquired hypofibrinogenemia and dysfibrinogenemia may be seen in patients with liver disease, disseminated intravascular coagulation (DIC), or hemophagocytic lymphohistiocytosis (HLH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and laboratory</strong> – The initial evaluation includes a personal and family history focusing on bleeding, thrombotic, and obstetric complications; a PT, aPTT, and thrombin time (TT; also called thrombin clotting time); and a plasma fibrinogen level. </p><p></p><p class="bulletIndent1">The following is supportive of a fibrinogen disorder in the appropriate clinical setting:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PT, aPTT, TT</strong> – The PT, aPTT, and TT all depend on production of a fibrin clot as the endpoint of the assay and are abnormal in hypo and dysfibrinogenemias if severe  (<a class="graphic graphic_algorithm graphicRef103926" href="/d/graphic/103926.html" rel="external">algorithm 2</a>). The sensitivity of these tests varies depending on the assay and laboratory-specific reagents, and prolongation will typically detect a fibrinogen level &lt;100 mg/dL, although some aPTT assays will not become prolonged unless the fibrinogen level is below 50 mg/dL. </p><p></p><p class="bulletIndent2">As a general rule, the TT and PT are more sensitive than the aPTT. Although the TT is a more sensitive screening test, its specificity is poor since there are other common causes for a prolonged TT. Similar to the TT, reptilase time (RT) is a useful screening test and is not affected by the presence of heparin; in some cases, prolongation of the RT may be more significant than the TT. If a mixing study has been done on one or more of these tests, it may show correction in the setting of afibrinogenemia or hypofibrinogenemia but not dysfibrinogenemia because a functionally abnormal fibrinogen may act as an inhibitor in a mixing study. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Thrombin time (TT)'</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Use of mixing studies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrinogen </strong>– The functional fibrinogen level will be low in afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia. Artifactually low levels of fibrinogen can be seen when blood clots in an improperly collected sample; if there is visible clotting in a plasma sample or the result is discordant with the clinical picture, the test should be repeated before embarking on an extensive laboratory evaluation.</p><p></p><p class="bulletIndent2">The plasma fibrinogen assay typically reports functional fibrinogen activity (also called clottable fibrinogen) as a level in mg/dL. The most common laboratory test uses the Clauss method, which measures time to clot formation after adding a high concentration of thrombin to citrated, platelet-poor patient plasma [<a href="#rid159">159-162</a>]. Functional assays measure only the fibrinogen that is incorporated into the clot; certain abnormal fibrinogens may produce an abnormally low level if they fail to be incorporated into the clot or may inhibit clotting of normal fibrinogen. In dysfibrinogenemia, the sensitivity and specificity of the Clauss method depend on the reagents, the methods, the treatment received, and the specific fibrinogen variant(s) [<a href="#rid163">163,164</a>]. The PT-derived fibrinogen overestimates fibrinogen activity in dysfibrinogenemia but is correlated to the antigen level [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for the cause</strong> – If the fibrinogen level is low, the need for additional testing depends on the clinical setting and the likelihood of other diagnoses. Testing for fibrinogen disorders is often pursued after more common conditions are ruled out, as described in the following examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an ill individual with a known or suspected acquired cause of hypofibrinogenemia, such as liver disease, DIC, or HLH, management is directed at resolving the underlying condition and preventing or treating bleeding and/or thrombosis. (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an individual with unexplained bleeding, thrombosis, and/or pregnancy morbidity after more common causes of these findings have been eliminated and a fibrinogen disorder is suspected, TT and fibrinogen antigen level should be obtained. Additional details of the evaluation depend on the patient and family history and the prominent clinical features, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/d/html/5436.html" rel="external">"Recurrent pregnancy loss: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an asymptomatic individual for whom the abnormality was an incidental finding, repeat fibrinogen level should be obtained for confirmation. Acquired conditions such as low-grade DIC, medication-induced abnormalities, and chronic liver disease should be ruled out first. If no apparent explanation is found, additional testing is indicated with TT, RT, and fibrinogen antigen level.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a relative of an individual with known hypofibrinogenemia or afibrinogenemia, screening with a PT, aPTT, TT, RT, fibrinogen activity, and antigen levels should be obtained. If abnormalities suggestive of a fibrinogen disorder are documented, genetic testing may be offered to identify the causative mutation (pathogenic variant); some fibrinogen variants are associated with a more specific clinical phenotype. (See <a class="local">'Diagnostic confirmation'</a> below.)</p><p></p><p class="bulletIndent1">Consultation with a specialized coagulation laboratory and/or a clinician with expertise in coagulation testing may be appropriate.</p><p></p><p class="headingAnchor" id="H6298538"><span class="h2">Diagnostic confirmation</span><span class="headingEndMark"> — </span>The following is confirmatory [<a href="#rid47">47,137</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Afibrinogenemia</strong> – Absent plasma fibrinogen using both a functional assay and an immunoassay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypofibrinogenemia</strong> – Decreased plasma fibrinogen (below the lower limit of the normal range; typically, &lt;150 mg/dL) using both a functional assay and an immunoassay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysfibrinogenemia</strong> – Discordance between functional and immunoreactive fibrinogen (low functional activity level with normal or elevated immunological level).</p><p></p><p class="headingAnchor" id="H3452578092"><span class="h2">Genetic testing and other specialized testing</span><span class="headingEndMark"> — </span>As with many genetic disorders, genetic testing has become increasingly available for confirming the diagnosis of congenital fibrinogen disorders. </p><p>Sequencing of the fibrinogen genes is offered through certain clinical laboratories. The advancement of next generation sequencing technologies makes it easier and cheaper to perform large-scale genetic analyses [<a href="#rid52">52</a>]. The usefulness of a prioritization scheme (and of skipping the analysis of most candidate exons in the fibrinogen cluster) is still reasonable in developing countries where the prevalence of fibrinogen disorders is higher. An efficient, step-wise genetic screening approach for congenital fibrinogen disorders targeting specific exons has been developed [<a href="#rid50">50</a>]. </p><p>If an inherited disorder is suspected, family history and genetic testing for disease-causing variants may be appropriate, although this testing is not required for diagnosis  (<a class="graphic graphic_algorithm graphicRef114258" href="/d/graphic/114258.html" rel="external">algorithm 1</a>). </p><p>Other specialized assays for fibrinogen (electrophoretic migration, fibrinopeptide release, and fibrin monomer aggregation) are generally available only in research laboratories. Identification of a familial variant may be helpful in evaluating asymptomatic family members of an affected individual, or for reproductive planning and prenatal diagnosis. It is also important to verify that the variant is indeed the cause of the clinical phenotype. </p><p class="headingAnchor" id="H6298614"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of bleeding and/or prolonged thrombin time</strong> – Other causes of bleeding include inherited factor deficiencies (eg, hemophilia) and acquired factor inhibitors. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a> and  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Reptilase time (RT)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like fibrinogen disorders, these may cause bleeding and abnormal clotting times. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike fibrinogen disorders, most of these other conditions do not prolong the prothrombin time (PT), activated partial thromboplastin time (aPTT), or thrombin time (TT). </p><p></p><p class="bulletIndent1">Other causes of a prolonged PT, aPTT, and TT include heparin, direct thrombin inhibitors (<a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>, and <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>); hypoalbuminemia; paraproteins (eg, as in multiple myeloma), which impair fibrinogen polymerization; and antibodies to thrombin (eg, in patients exposed to bovine thrombin preparations). Like fibrinogen disorders, some of these may be associated with bleeding. Unlike fibrinogen disorders, these conditions are not associated with abnormalities of fibrinogen function or immunoreactive fibrinogen levels. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Thrombin time (TT)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of thrombosis and/or pregnancy loss</strong> – Other causes of thrombosis include inflammatory states, antiphospholipid syndrome, and inherited thrombophilias. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/1090.html" rel="external">"Cryptogenic stroke and embolic stroke of undetermined source (ESUS)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Like fibrinogen disorders, these conditions may be inherited or acquired. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlike fibrinogen disorders, these other conditions do not cause prolongation of the PT, aPTT, and TT or abnormalities of fibrinogen function or immunoreactive fibrinogen levels.</p><p></p><p class="headingAnchor" id="H27"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The main goal of management is to prevent or treat serious bleeding, thrombosis, and obstetric complications. Not all patients require an intervention since many individuals with mild dysfibrinogenemia or hypofibrinogenemia are asymptomatic.</p><p>Evidence to guide management is scarce because the inherited disorders are extremely rare and heterogeneous. Our practice is mostly based on our clinical experience and that of other experts. Previous approaches that have worked in a specific patient are noted and used for that patient (and for affected relatives). Our practice is generally consistent with 2004 and 2014 guidelines from the United Kingdom Haemophilia Centres Doctors' Organisation (UKHCDO) and a 2016 consensus from a panel with expertise in bleeding disorders [<a href="#rid137">137,165,166</a>].</p><p class="headingAnchor" id="H3147071630"><span class="h2">Treatment/prevention of bleeding</span></p><p class="headingAnchor" id="H174230803"><span class="h3">Acute bleeding</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinogen target</strong> – For a fibrinogen disorder and clinically important bleeding or emergency surgery that would cause clinically important bleeding without other coagulation factor deficiencies, we suggest administration of fibrinogen replacement to raise the functional fibrinogen &gt;150 mg/dL until hemostasis is achieved, using the higher range for more severe bleeding or more hemostatically challenging surgery. For the most severe bleeding (such as intracerebral bleeding), a target of 150 to 200 mg/dL is used [<a href="#rid165">165</a>].</p><p></p><p class="bulletIndent1">These targets are based on observational data from case reports and small series that suggest hemostasis is likely to be intact with functional fibrinogen &gt;100 mg/dL and demonstrate a low risk of adverse effects with administration of <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> in individuals with inherited fibrinogen disorders [<a href="#rid167">167-172</a>]. Randomized trials comparing other fibrinogen thresholds or other therapies have not been conducted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of product</strong> – Products for replacing fibrinogen include fibrinogen concentrates, Cryoprecipitate, and plasma products such as fresh frozen plasma (FFP). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital fibrinogen disorders</strong> – For congenital fibrinogen disorders, we suggest a <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> rather than Cryoprecipitate or a plasma product. This is a US Food and Drug Administration (FDA)-approved indication for fibrinogen concentrates [<a href="#rid173">173,174</a>]. Cryoprecipitate may be used if a fibrinogen concentrate is not available, and plasma may be used if Cryoprecipitate is not available. The rationale for preferring a fibrinogen concentrate includes the small volume, ease of administration, lower risk of transfusion reactions and volume overload, and likely lower risk of thromboembolic complications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired hypofibrinogenemias </strong>– Recommendations regarding choice of product and supporting evidence are presented in topic reviews on the specific conditions. (See  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate", section on 'Use in specific settings'</a>.)</p><p></p><p class="bulletIndent1">There is no role for prothrombin complex concentrates (PCCs) in treating fibrinogen disorders; PCCs do not contain fibrinogen. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and duration of therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> – (See  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate", section on 'Cryoprecipitate (dosing and administration)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> – Once hemostasis is established, a target fibrinogen level of &gt;50 mg/dL is used until wound healing is complete. For individuals with afibrinogenemia or severe hypofibrinogenemia who have had a major bleed, secondary prophylaxis may be used to maintain trough activity levels &gt;50 to 100 mg/dL. (See <a class="local">'Routine prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – (See  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate", section on 'Cryoprecipitate adverse effects'</a> and  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate", section on 'Fibrinogen concentrate adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional treatments</strong> – For heavy menstrual bleeding, hormonal therapies and/or antifibrinolytic agents may be appropriate depending on the needs of the patient. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1">Management of bleeding in acquired fibrinogen disorders is more complex because other procoagulant and anticoagulant factors may also be abnormal. If fibrinogen deficiency is the predominant abnormality, fibrinogen concentrates may be appropriate, whereas individuals with multiple factor deficiencies may benefit from plasma products. An analysis of patients from the Fibrinogen Early in Severe Trauma studY (FEISTY) showed that transfusion of Cryoprecipitate was able to restore key fibrinolytic regulators, and in an in vitro study, Cryoprecipitate limited plasmin generation, allowing stronger clots to form relative to treatment with <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> [<a href="#rid175">175</a>].</p><p></p><p class="bulletIndent1">A review of the role of fibrinogen concentrates in acquired bleeding disorders has evaluated the available evidence and concluded that it is premature to advise routine use [<a href="#rid176">176</a>]. Arguments in favor of and against routine use have also been published [<a href="#rid177">177,178</a>]. Management of bleeding in these conditions is discussed in detail separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trauma</strong> – (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients"</a> and  <a class="medical medical_review" href="/d/html/127887.html" rel="external">"Approach to shock in the adult trauma patient"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postpartum hemorrhage</strong> – (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver disease</strong> – (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disseminated intravascular coagulation (DIC)</strong> – (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H4285507662"><span class="h3">Elective surgery</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Planning</strong> – Multidisciplinary consultation that includes a hemostasis expert is prudent prior to any elective procedure to determine the expected bleeding risk and develop a treatment plan. Evidence to guide decision-making comes from case series [<a href="#rid167">167-171</a>]. Decisions should take into account the type of surgery, the severity of fibrinogen disorder, and the personal and/or family bleeding and thrombosis phenotypes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a history of bleeding and those with congenital afibrinogenemia (regardless of personal or family bleeding history) should receive fibrinogen replacement prior to elective procedures that carry a risk of bleeding [<a href="#rid165">165</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with moderate hypofibrinogenemia (eg, fibrinogen activity level &gt;50 mg/dL) without a bleeding history can often be managed conservatively without prophylactic replacement therapy for low bleeding risk procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – If fibrinogen replacement is used, the first dose is given on the day of the procedure and an adequate level is confirmed before beginning the procedure. A target level of &gt;100 to 150 mg/dL for major surgery (often &gt;150 mg/dL) and &gt;50 mg/dL for minor surgery is reasonable [<a href="#rid42">42,172</a>]. Global hemostasis testing such as thromboelastography (TEG) is evolving and may be used to guide fibrinogen dosing at some institutions. (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'</a>.)</p><p></p><p class="bulletIndent1">The level is maintained above &gt;50 mg/dL postoperatively until hemostasis is assured. Some experts use a target fibrinogen level of &gt;100 mg/dL until wound healing [<a href="#rid179">179</a>]. The duration of therapy can vary from a few doses to up to two to three weeks, with longer durations for the more hemostatically challenging procedures. Dosing calculations are discussed below. (See <a class="local">'Fibrinogen concentrate: Dosing and monitoring'</a> below and <a class="local">'Cryoprecipitate and Fresh Frozen Plasma (FFP): Dosing and monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrin glue</strong> – Fibrin glue may be used for surfaces that are not amenable to suturing, cautery, or other procedures. (See  <a class="medical medical_review" href="/d/html/7938.html" rel="external">"Fibrin sealants"</a> and  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antifibrinolytic agents</strong> – Antifibrinolytic agents are controversial; they may be appropriate for some individuals, especially those undergoing mucosal or dental procedures. However, there may be an increased risk of thrombotic complications, and these agents should be used with caution in individuals with dysfibrinogenemia with a thrombotic fibrinogen variant or a personal or family history of thrombosis [<a href="#rid137">137,172</a>]. (See <a class="local">'Antifibrinolytic agents'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thromboprophylaxis </strong>– Mechanical or pharmacologic thromboprophylaxis is important and appropriate, with the specific therapy tailored to the procedure and thromboembolic risk. (See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="headingAnchor" id="H883228816"><span class="h3">Routine prophylaxis</span><span class="headingEndMark"> — </span>Most patients with fibrinogen disorders are treated with "on demand" fibrinogen replacement and do not require routine primary prophylaxis in the absence of a history of a severe bleeding event. (See <a class="local">'Acute bleeding'</a> above and <a class="local">'Elective surgery'</a> above and <a class="local">'Conception and pregnancy'</a> below.)</p><p>However, some individuals with afibrinogenemia or severe hypofibrinogenemia (fibrinogen &lt;10 mg/dL) may be treated prophylactically with fibrinogen concentrates or Cryoprecipitate, similar to routine factor replacement in severe hemophilia, especially if they have had a previous bleeding event (ie, as secondary prophylaxis) [<a href="#rid47">47,141</a>]. Due to the high rate of cerebral bleeding in patients with afibrinogenemia, many experts use primary prophylaxis in this population [<a href="#rid63">63,139</a>]. </p><p>In a series of 204 individuals with congenital afibrinogenemia, 35 percent were treated with prophylactic <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> due to severe bleeding phenotype [<a href="#rid63">63</a>]. (See <a class="local">'Bleeding and abnormal clotting times'</a> above.)</p><p>It is difficult to assess the efficacy of primary and secondary prophylaxis due to small numbers of affected individuals, and practice must be individualized according to the patient's bleeding and thrombotic history, response to previous therapies, and access to fibrinogen product [<a href="#rid141">141</a>]. A target trough fibrinogen level of 50 mg/dL is considered reasonable for prophylaxis against bleeding [<a href="#rid165">165</a>]. (See <a class="local">'Fibrinogen concentrate: Dosing and monitoring'</a> below.)</p><p>Additional settings in which prophylactic administration of fibrinogen replacement may be appropriate include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy, especially if there has been prior pregnancy loss attributed to the fibrinogen disorder. (See <a class="local">'Conception and pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation for a thrombotic complication, especially if there is a history of bleeding, afibrinogenemia, or severe hypofibrinogenemia. (See <a class="local">'Treatment and prevention of thrombosis'</a> below.)</p><p></p><p class="headingAnchor" id="H1979341027"><span class="h3">Fibrinogen concentrate: Dosing and monitoring</span><span class="headingEndMark"> — </span>Fibrinogen concentrates (eg, RiaSTAP, Haemocomplettan, FIBRYGA [previously called FIBRYNA]) are prepared from pooled human plasma and are available as lyophilized powders (approximately 1 g [1000 mg]/vial) that are reconstituted in a small volume. Other available products include Clottafact (France) and FibClot (Europe).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">Fibrinogen concentrate</a> is used to treat or prevent bleeding and to prevent pregnancy loss in patients with congenital afibrinogenemia or moderate to severe hypofibrinogenemia. </p><p></p><p class="bulletIndent1">Fibrinogen concentrates are not routinely used for the management of dysfibrinogenemia. Replacement guidelines for patients with dysfibrinogenemia are not well defined due to the heterogeneity of the phenotype and the greater risk of thrombosis. Fibrinogen replacement is usually limited to on-demand if there is abnormal bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dose</strong> – The dose and intensity of monitoring depend on the clinical situation, with more aggressive treatment for more severe bleeding or more hemostatically challenging surgery.</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Dose = [Target fibrinogen level – measured fibrinogen level] ÷ correction factor.</p></div></div><p></p><p class="bulletIndent2">The fibrinogen level is expressed in mg/dL. The correction factor is in mg/dL or mg/kg. The correction factor is 1.7 for RiaSTAP and Haemocomplettan and 1.8 for FIBRYGA. Thus, the dose in mg is calculated as follows:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><span class="glyph">•</span><strong>RiaSTAP and Haemocomplettan</strong> – Dose (in mg) = [weight (in kg) x desired increase (in mg/dL)] ÷ 1.7</p></div></div><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><span class="glyph">•</span><strong>FIBRYGA</strong> – Dose (in mg) = [weight (in kg) x desired increase (in mg/dL)] ÷ 1.8. For FIBRYGA in children &lt;12 years of age, divide by 1.4 instead of 1.8.</p></div></div><p></p><p class="bulletIndent1">If the patient's fibrinogen level is not known, the product information states that a dose of 70 mg/kg can be used for initial dosing. Dosing in early pregnancy is discussed below. (See <a class="local">'Conception and pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Example calculation</strong> – A 50 kg individual with fibrinogen 0 mg/dL and a desired level of 150 mg/dL would be given 4100 to 4400 mg, rounded to the nearest vial size (approximately four 1000 mg vials).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent doses</strong> – Additional doses are based on the patient's trough plasma fibrinogen levels rather than a fixed dose or schedule, as pharmacokinetics vary widely among individuals according to age and weight [<a href="#rid141">141,180,181</a>]. The amount of <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> in subsequent doses will be lower (approximately one-half to one-third the initial dose) since the patient's fibrinogen level will not return to zero between doses. </p><p></p><p class="bulletIndent1">The half-life of fibrinogen is 3 to 3.5 days (77 to 88 hours) [<a href="#rid168">168</a>]. As a general rule, plasma fibrinogen levels can be measured once per day (more frequently if increased or unexpected bleeding occurs); the interval may be extended as healing is completed. </p><p></p><p class="bulletIndent1">A common dosing interval for postoperative management is every two to four days depending on the trough level and the underlying indication for replacement. If the trough level is too low, it is preferable to shorten the dosing interval (give more frequent infusions) rather than increasing the amount of fibrinogen given in each dose [<a href="#rid165">165</a>].</p><p></p><p>In a 2006 survey of clinicians who provided prophylaxis to individuals with afibrinogenemia or severe hypofibrinogenemia, a median fibrinogen dose of 53 mg/kg was given approximately once per week (range, 18 to 120 mg/kg; schedule, once per week to once per month) [<a href="#rid141">141</a>].</p><p>Cost may be a consideration in the availability of <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a>. A survey of 30 transfusion medicine fellowship directors in the United States found that the majority do not use fibrinogen concentrate for bleeding, with cost and off-label indication as one of the primary reasons [<a href="#rid182">182</a>].</p><p class="headingAnchor" id="H4032884770"><span class="h3">Cryoprecipitate and Fresh Frozen Plasma (FFP): Dosing and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Cryoprecipitate (cryo) can be used as a source of fibrinogen when <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> is unavailable. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – One unit of Cryoprecipitate contains all of the fibrinogen present in one unit of whole blood (approximately 200 to 400 mg) in a volume of 10 to 20 mL  (<a class="graphic graphic_table graphicRef53854" href="/d/graphic/53854.html" rel="external">table 5</a>). Each unit of Cryoprecipitate raises the plasma fibrinogen concentration by approximately 7 to 10 mg/dL, with a half-life of approximately four days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For severe bleeding, 1 unit per 5 kg of body weight (eg, 10 units in a 50 kg individual) can be administered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For minor bleeding, 1 unit per 10 kg (eg, 5 units in a 50 kg individual) may be sufficient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and repeat dosing</strong> – As with <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a>, the plasma fibrinogen level is monitored at the appropriate interval (daily for major bleeding or major surgery, less often for minor bleeding or minor surgery), and repeat doses are administered to maintain the level above the appropriate threshold.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Complications with Cryoprecipitate include transfusion reactions (allergic, infectious) and thrombosis [<a href="#rid183">183,184</a>]. Extremely rarely, a patient with afibrinogenemia may have developed antibodies to fibrinogen following replacement therapy [<a href="#rid185">185,186</a>]. Additional information is presented separately. (See  <a class="medical medical_review" href="/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma Cryoprecipitate is unavailable</strong> – A plasma product such as FFP or Plasma Frozen Within 24 Hours of Collection (PF24) may be used. Dosing is approximately 10 to 15 mL/kg  (<a class="graphic graphic_table graphicRef53854" href="/d/graphic/53854.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/7920.html" rel="external">"Clinical use of plasma components"</a>.)</p><p></p><p class="headingAnchor" id="H632750000"><span class="h3">Antifibrinolytic agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">Tranexamic acid</a> or epsilon-aminocaproic acid may be used, especially to treat or prevent mucosal bleeding. However, systemic administration has been associated with thrombosis, and these agents should not be used (or should be used with extreme caution) in patients with a personal or family history of thrombosis [<a href="#rid137">137</a>].</p><p>Local treatment (eg, 5 percent mouthwash solution 10 mL four times daily for 7 to 10 days) may be useful in oral or dental surgery [<a href="#rid187">187</a>].</p><p class="headingAnchor" id="H1334638904"><span class="h2">Conception and pregnancy</span><span class="headingEndMark"> — </span>Individuals with congenital fibrinogen disorders are at increased risk of pregnancy loss, subchorionic hematomas, placental abruption, and postpartum hemorrhage. Pregnancy in an individual with a congenital fibrinogen disorder is considered high risk, and consultation between experts in rare bleeding disorders and high-risk pregnancy is advised [<a href="#rid165">165</a>]. </p><p>The first case of a successful pregnancy in an individual with afibrinogenemia supported by fibrinogen infusion was reported in 1985 [<a href="#rid188">188</a>]. Before the availability of routine fibrinogen replacement, individuals with afibrinogenemia were unable to have a successful pregnancy. Fibrinogen appears to be required for normal placenta maintenance during the first trimester of pregnancy. (See <a class="local">'Functions in hemostasis and other processes'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complication rate</strong> – A systematic review of 188 pregnancies (70 individuals with hereditary fibrinogen disorders) from 1985 to 2018 confirmed a high rate of adverse obstetric outcomes [<a href="#rid189">189</a>]. Fibrinogen was administered in one-half of the pregnancies with afibrinogenemia and 14 to 25 percent of pregnancies with other congenital fibrinogen disorders. The following complications were observed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy loss (miscarriage) in 15 of 35 pregnancies (43 percent) with afibrinogenemia and 27 of 63 pregnancies (43 percent) with dysfibrinogenemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metrorrhagia in 22 percent of pregnancies during the first trimester.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Placental abruption in 8 percent (quantitative and qualitative disorders).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High incidence of postpartum hemorrhage (19 percent), although none were observed in women with afibrinogenemia receiving fibrinogen replacement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postpartum thrombosis in six pregnancies.</p><p></p><p class="bulletIndent1">The Fibrinogest study reported on the natural course of 425 pregnancies in 159 individuals with low fibrinogen between 2019 and 2021, excluding those with afibrinogenemia [<a href="#rid146">146</a>]. There were 49 individuals with hypofibrinogenemia, 95 with dysfibrinogenemia, and 15 with hypodysfibrinogenemia. Only 28 patients (8.9 percent) received fibrinogen infusions. Comparing with epidemiological data in Europe, there were increased rates of retroplacental hematoma (4.1 percent), postpartum hemorrhage (19.9 percent), and postpartum venous thromboembolism (VTE; 1.6 percent). In contrast, the rate of miscarriage (12.9 percent) was not higher than found in the French general population. Other smaller studies reported a higher prevalence of miscarriage (up to 49.7 percent) [<a href="#rid54">54,55,189</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The following approaches may be helpful to reduce pregnancy loss, bleeding, and/or thrombosis during the pregnancy and postpartum:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Afibrinogenemia or severe hypofibrinogenemia (fibrinogen &lt;50 mg/dL) </strong>– Individuals with congenital afibrinogenemia or severe hypofibrinogenemia should have preconception and genetic counseling, and they should be considered for preconception fibrinogen replacement or fibrinogen administration as soon as pregnancy is confirmed. This practice is based on evidence from case reports and small series [<a href="#rid137">137,167,190-194</a>]. A 2017 joint United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) and Royal College of Obstetricians and Gynaecologists (RCOG) guideline provides guidance for the management of pregnancy and delivery [<a href="#rid195">195</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We use a target trough level of 100 mg/dL throughout pregnancy, with monitoring every one to two weeks. Some experts use a lower trough level (&gt;50 to 60 mg/dL) during the first trimester [<a href="#rid165">165</a>]. If a previous pregnancy has been unsuccessful, a higher trough level may be appropriate [<a href="#rid167">167</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The required dose is likely to increase significantly as the pregnancy progresses (due to increased clearance). Typical reported doses range from 2 g twice weekly during the first trimester to 5 g three to four times per week close to term [<a href="#rid167">167</a>]. If needed, it is preferable to increase the frequency of administration rather than the dose.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>During labor and for a minimum of 24 hours postpartum, target a fibrinogen of at least 150 to 200 mg/dL; the UKHCDO/RCOG 2017 guideline recommends target levels of 150 to 200 mg/dL for at least three days [<a href="#rid195">195</a>]. Continuous infusion may prevent placental abruption. We use a target of 200 mg/dL for cesarean delivery. Early administration of <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> should be considered for postpartum bleeding. Thromboprophylaxis is considered until discharge per standard of care in the general obstetric population.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>After the first 24 hours postpartum, a fibrinogen level &gt;50 mg/dL is appropriate until healing is complete. Consideration should be given to a higher trough level for the first 72 hours if there is a bleeding phenotype or history of postpartum hemorrhage.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>To minimize thromboembolic risk, we avoid overcorrecting fibrinogen levels. If prophylactic dose low molecular weight heparin (LMWH) is indicated, it can be given while providing fibrinogen replacement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate hypofibrinogenemia (fibrinogen between 50 and the lower limit of the reference range, typically 150 mg/dL)</strong> – Individuals with mild hypofibrinogenemia (50 to 90 mg/dL) and moderate hypofibrinogenemia (100 mg/dL up to the lower limit of the reference range) are usually asymptomatic [<a href="#rid67">67</a>]. However, pregnancy could be associated with increased risk of miscarriage, bleeding, and postpartum hemorrhage. In individuals with moderate hypofibrinogenemia (fibrinogen activity 50 to 100 mg/dL), fibrinogen replacement targeting a trough fibrinogen level 100 mg/dL throughout the pregnancy to avoid the risk of placental abruption can be considered. </p><p></p><p class="bulletIndent2">Fibrinogen administration is recommended for labor and delivery. Fibrinogen administration during pregnancy has not been well established; it should be considered if there is a history of recurrent miscarriages or bleeding during pregnancy.</p><p></p><p class="bulletIndent2">In a series of 11 individuals with hypofibrinogenemia (mean fibrinogen 72 mg/dL; range 48 to 111 mg/dL), pregnancies were uneventful [<a href="#rid196">196</a>]. Fibrinogen replacement was provided for labor and delivery in all (mean fibrinogen at delivery, 153 mg/dL; range 79 to 254 mg/dL); it was not clear how many received replacement during pregnancy. There was no preterm delivery, postpartum hemorrhage, or thrombosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysfibrinogenemia</strong> – Management is challenging because clinical phenotypes and levels of functional fibrinogen are more variable; evidence to guide therapy is extremely limited [<a href="#rid167">167</a>]. The patient's previous thrombosis or bleeding history should guide treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals with no history of bleeding or thrombosis should be discussed by a multidisciplinary team. Routine use of replacement therapy during pregnancy in these individuals is not indicated. Individuals with fibrinogen activity &lt;50 mg/dL are at greater risk of spontaneous abortion and postpartum bleeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>During pregnancy, fibrinogen replacement to raise the fibrinogen level to &gt;150 mg/dL is recommended in case of vaginal bleeding. Others can be treated expectantly with vaginal delivery and fibrinogen given only if bleeding occurs or if Cesarean delivery is required [<a href="#rid167">167</a>]. Thromboprophylaxis is indicated when pregnancy is associated with a known dysfibrinogenemia with a thrombotic variant.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At delivery, a fibrinogen level &gt;150 mg/dL is required for neuraxial anesthesia; target fibrinogen &gt;150 mg/dL for vaginal delivery in individuals with bleeding phenotype, or &gt;200 mg/dL for cesarean delivery. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monitor closely for bleeding for 72 hours postpartum, with prompt use of fibrinogen replacement and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> if there's postpartum bleeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Management of recurrent miscarriages in individuals with dysfibrinogenemia is controversial; evidence is limited to case reports. Therapy may include fibrinogen replacement, anticoagulation, or both [<a href="#rid167">167</a>]. One report described successful pregnancy in three of four related individuals with recurrent pregnancy loss who were treated with continuous fibrinogen replacement as soon as pregnancy was diagnosed [<a href="#rid197">197</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Strong consideration should be given to postpartum thromboprophylaxis (LMWH) if there is a personal or family history of thrombosis and those without previous bleeding [<a href="#rid165">165</a>]. In a registry of patients with a thrombophilic dysfibrinogenemia, 7 of 15 developed postpartum thrombosis [<a href="#rid55">55</a>]. Others may be managed with mechanical thromboprophylaxis. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="headingAnchor" id="H2436160941"><span class="h2">Treatment and prevention of thrombosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Evidence to guide treatment is limited. In general, individuals with thrombotic complications with an abnormal fibrinogen should be treated with anticoagulation unless there is a contraindication  (<a class="graphic graphic_table graphicRef107527" href="/d/graphic/107527.html" rel="external">table 6</a>). Low molecular weight (LMW) heparins are preferred for venous thrombosis. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> remains an option if the baseline prothrombin time (PT) is not prolonged. There are limited data on the efficacy and safety of the direct oral anticoagulants in these conditions [<a href="#rid198">198</a>]. The duration of anticoagulation should be similar to the general population, except for carriers of thrombophilic dysfibrinogenemia [<a href="#rid172">172</a>].</p><p></p><p class="bulletIndent1">Individuals with fibrinogen &gt;50 mg/dL can generally be safely anticoagulated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For congenital afibrinogenemia, anticoagulation should be accompanied by fibrinogen replacement therapy to reduce the risk of bleeding complications [<a href="#rid165">165</a>]. (See <a class="local">'Fibrinogen concentrate: Dosing and monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with inherited dysfibrinogenemias do not need fibrinogen replacement; these individuals are managed with anticoagulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For acquired dysfibrinogenemias, treatment of the underlying cause is pursued along with anticoagulation, as discussed separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Venous thromboembolism (VTE)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Routine VTE prophylaxis is generally not used outside of high-risk settings such as perioperatively, during an acute medical illness, or postpartum. </p><p></p><p class="bulletIndent1">Individuals with a known thrombophilic fibrinogen variant are managed similarly to other individuals with thrombophilia. <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> can be used without replacement therapy in some individuals with afibrinogenemia after evaluation of the bleeding risk, as noted in a survey of specialized centers [<a href="#rid165">165</a>]. (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a> and  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p>All individuals with a thrombophilic fibrinogen variant should be educated about additional risk factors for thrombosis, signs and symptoms of thromboembolism, and risk reduction strategies (such as avoiding prolonged immobilization). (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Acquired risk factors'</a>.)</p><p class="headingAnchor" id="H1215153822"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119328.html" rel="external">"Society guideline links: Acquired bleeding disorders"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119326.html" rel="external">"Society guideline links: Rare inherited bleeding disorders"</a>.)</p><p class="headingAnchor" id="H9299846"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role in hemostasis</strong> – Fibrinogen circulates at 200 to 400 mg/dL and increases as an acute phase reactant. During clotting, fibrinogen is converted to fibrin  (<a class="graphic graphic_figure graphicRef68948" href="/d/graphic/68948.html" rel="external">figure 1</a>), which polymerizes and becomes crosslinked  (<a class="graphic graphic_figure graphicRef62012" href="/d/graphic/62012.html" rel="external">figure 3</a>); this provides a major structural component of the clot. The fibrin meshwork  (<a class="graphic graphic_figure graphicRef142944" href="/d/graphic/142944.html" rel="external">figure 2</a>) also supports platelet aggregation and serves as a template for thrombin, fibrinolytic proteins, wound healing, and placental implantation. (See <a class="local">'Biology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic disorders</strong> – Congenital fibrinogen disorders can be caused by variants in <em>FGA</em>, <em>FGB</em>, or <em>FGG</em>  (<a class="graphic graphic_figure graphicRef123075" href="/d/graphic/123075.html" rel="external">figure 5</a>). These rare disorders can be quantitative (afibrinogenemia and hypofibrinogenemia), qualitative (dysfibrinogenemia), or both (hypodysfibrinogenemia). (See <a class="local">'Heritable (genetic) disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired disorders</strong> – Acquired hypofibrinogenemia and dysfibrinogenemia can be caused by liver disease, disseminated intravascular coagulation (DIC), hemophagocytic lymphohistiocytosis (HLH), and other conditions  (<a class="graphic graphic_table graphicRef55144" href="/d/graphic/55144.html" rel="external">table 1</a>). Cryofibrinogenemia (cold insoluble fibrinogen in plasma but not serum  (<a class="graphic graphic_figure graphicRef142943" href="/d/graphic/142943.html" rel="external">figure 4</a>)) is generally caused by autoimmune disorders, infections, or malignancies. (See <a class="local">'Acquired abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Fibrinogen disorders can present with bleeding or incidentally; thrombosis, obstetric complications, and other findings may occur  (<a class="graphic graphic_table graphicRef114456" href="/d/graphic/114456.html" rel="external">table 4</a>). Individuals with congenital afibrinogenemia have a high rate of bleeding, thrombosis, bone cysts, and pregnancy loss. The prothrombin time (PT), activated partial thromboplastin time (aPTT), and/or thrombin time (TT) are typically prolonged; fibrinogen levels and/or function are decreased. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Assess the personal and family history of bleeding, thrombotic, and obstetric complications and obtain standard laboratory testing  (<a class="graphic graphic_algorithm graphicRef114258" href="/d/graphic/114258.html" rel="external">algorithm 1</a>). Specialized testing may be indicated in some individuals, after consultation with a bleeding disorders expert. Diagnosis is confirmed by low plasma fibrinogen level and/or reduced function. (See <a class="local">'Diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential includes inherited and acquired bleeding and thrombotic disorders and other causes of pregnancy morbidity. Prolongation of the PT, aPTT, and TT may be caused by some anticoagulants, paraproteins in multiple myeloma, and antibodies in patients exposed to bovine thrombin. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bleeding</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Target fibrinogen level</strong> – For patients with afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia who have clinically important bleeding or require emergency surgery, we suggest raising the functional fibrinogen level to &gt;100 to 150 mg/dL (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The higher range is used for more severe bleeding or more hemostatically challenging surgery. For intracerebral bleeding, the target is 150 to 200 mg/dL. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Product </strong>– When fibrinogen replacement is required for a congenital fibrinogen disorder, we suggest <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> rather than Cryoprecipitate or plasma (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This is an approved indication based on lower risk of transfusion reactions and volume overload. Management of bleeding in acquired fibrinogen disorders is more complex because other coagulation factors are also likely to be abnormal; Cryoprecipitate and/or other blood products and clotting factor concentrates may be used. (See <a class="local">'Acute bleeding'</a> above and <a class="local">'Fibrinogen concentrate: Dosing and monitoring'</a> above and <a class="local">'Cryoprecipitate and Fresh Frozen Plasma (FFP): Dosing and monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong> – Elective surgery is managed in consultation with a hemostasis expert. Interventions may include fibrinogen replacement, fibrin glue, and/or an antifibrinolytic agent. More aggressive thromboprophylaxis may be appropriate in individuals with thrombotic variants. (See <a class="local">'Elective surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylaxis</strong> – For most patients with congenital fibrinogen disorders who have not had a severe bleed, we suggest not using routine prophylaxis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Due to the high risk of cerebral bleeding in afibrinogenemia, many experts use primary prophylaxis in these individuals. </p><p></p><p class="bulletIndent2">Secondary prophylaxis may be appropriate after a life-threatening bleed, and primary prophylaxis may be appropriate in selected individuals with a severe familial bleeding phenotype. A period of prophylactic fibrinogen may be reasonable during pregnancy or if anticoagulation is required, especially for severe deficiency. (See <a class="local">'Routine prophylaxis'</a> above and <a class="local">'Conception and pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis</strong> – Thrombosis is treated with anticoagulation; standard prophylactic indications should be followed. (See <a class="local">'Treatment and prevention of thrombosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Medved L, Weisel JW, Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 7:355.</a></li><li><a class="nounderline abstract_t">de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35:356.</a></li><li><a class="nounderline abstract_t">Behague I, Poirier O, Nicaud V, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93:440.</a></li><li><a class="nounderline abstract_t">Lee AJ, Fowkes FG, Lowe GD, et al. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999; 81:553.</a></li><li><a class="nounderline abstract_t">Falls LA, Farrell DH. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. J Biol Chem 1997; 272:14251.</a></li><li><a class="nounderline abstract_t">Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102:535.</a></li><li><a class="nounderline abstract_t">Collet JP, Nagaswami C, Farrell DH, et al. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004; 24:382.</a></li><li><a class="nounderline abstract_t">Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. Blood 2009; 114:3994.</a></li><li><a class="nounderline abstract_t">Litvinov RI, Pieters M, de Lange-Loots Z, Weisel JW. Fibrinogen and Fibrin. Subcell Biochem 2021; 96:471.</a></li><li><a class="nounderline abstract_t">Tennent GA, Brennan SO, Stangou AJ, et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109:1971.</a></li><li class="breakAll">Weisel JW, Litvinov RI. Fibrin formation, structure and properties. In: Fibrous Proteins: Structures and Mechanisms (Subcellular Biochemistry), Parry D, Squire J (Eds), Springer, 2017. Vol 82, p.405.</li><li><a class="nounderline abstract_t">Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation. Thromb Haemost 2004; 92:234.</a></li><li><a class="nounderline abstract_t">Galanakis D, Nuovo G, Spitzer S, et al. Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications. Thromb Res 1996; 81:263.</a></li><li><a class="nounderline abstract_t">Green F, Humphries S. Control of plasma fibrinogen levels. Baillieres Clin Haematol 1989; 2:945.</a></li><li><a class="nounderline abstract_t">Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21:1574.</a></li><li><a class="nounderline abstract_t">Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22:933.</a></li><li><a class="nounderline abstract_t">Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125:1387.</a></li><li><a class="nounderline abstract_t">Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972; 22:681.</a></li><li><a class="nounderline abstract_t">Meade TW, Chakrabarti R, Haines AP, et al. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1:153.</a></li><li><a class="nounderline abstract_t">Soria J, Soria C, Samama M, et al. Human platelet fibrinogen: a protein different from plasma fibrinogen. Pathol Biol (Paris) 1976; 24 Suppl:15.</a></li><li><a class="nounderline abstract_t">Francis CW, Nachman RL, Marder VJ. Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost 1984; 51:84.</a></li><li><a class="nounderline abstract_t">Galanakis D, Spitzer S, Scharrer I. Unusual A alpha 16Arg--&gt;Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings. Blood Coagul Fibrinolysis 1993; 4:67.</a></li><li><a class="nounderline abstract_t">Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 1997; 4:357.</a></li><li><a class="nounderline abstract_t">Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008; 111:4854.</a></li><li><a class="nounderline abstract_t">Standeven KF, Carter AM, Grant PJ, et al. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110:902.</a></li><li><a class="nounderline abstract_t">Pieters M, Wolberg AS. Fibrinogen and fibrin: An illustrated review. Res Pract Thromb Haemost 2019; 3:161.</a></li><li><a class="nounderline abstract_t">Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107:2326.</a></li><li><a class="nounderline abstract_t">Ajjan R, Lim BC, Standeven KF, et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111:643.</a></li><li><a class="nounderline abstract_t">Lovely RS, Falls LA, Al-Mondhiry HA, et al. Association of gammaA/gamma' fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88:26.</a></li><li><a class="nounderline abstract_t">Mannila MN, Lovely RS, Kazmierczak SC, et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007; 5:766.</a></li><li><a class="nounderline abstract_t">Duval C, Baranauskas A, Feller T, et al. Elimination of fibrin γ-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. Proc Natl Acad Sci U S A 2021; 118.</a></li><li><a class="nounderline abstract_t">Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25:311.</a></li><li><a class="nounderline abstract_t">Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267:24259.</a></li><li><a class="nounderline abstract_t">Soria J, Mirshahi S, Mirshahi SQ, et al. Fibrinogen αC domain: Its importance in physiopathology. Res Pract Thromb Haemost 2019; 3:173.</a></li><li><a class="nounderline abstract_t">Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg--&gt;Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994; 84:3709.</a></li><li><a class="nounderline abstract_t">Sugo T, Nakamikawa C, Takebe M, et al. Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. Blood 1998; 91:3282.</a></li><li><a class="nounderline abstract_t">Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245:126.</a></li><li><a class="nounderline abstract_t">Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80:1.</a></li><li><a class="nounderline abstract_t">Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:177.</a></li><li><a class="nounderline abstract_t">de Bosch NB, Mosesson MW, Ruiz-Sáez A, et al. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88:253.</a></li><li><a class="nounderline abstract_t">Nagler M, Kremer Hovinga JA, Alberio L, et al. Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review. Thromb Haemost 2016; 116:722.</a></li><li><a class="nounderline abstract_t">Casini A, de Moerloose P, Neerman-Arbez M. Clinical Features and Management of Congenital Fibrinogen Deficiencies. Semin Thromb Hemost 2016; 42:366.</a></li><li><a class="nounderline abstract_t">Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114:1929.</a></li><li><a class="nounderline abstract_t">Juang LJ, Hur WS, Silva LM, et al. Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA. Blood 2022; 139:1302.</a></li><li><a class="nounderline abstract_t">Suh TT, Holmbäck K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9:2020.</a></li><li><a class="nounderline abstract_t">Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14:1151.</a></li><li><a class="nounderline abstract_t">de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39:585.</a></li><li><a class="nounderline abstract_t">Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21:577.</a></li><li><a class="nounderline abstract_t">Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936:89.</a></li><li><a class="nounderline abstract_t">Casini A, Blondon M, Tintillier V, et al. Mutational Epidemiology of Congenital Fibrinogen Disorders. Thromb Haemost 2018; 118:1867.</a></li><li><a class="nounderline abstract_t">Richard M, Celeny D, Neerman-Arbez M. Mutations Accounting for Congenital Fibrinogen Disorders: An Update. Semin Thromb Hemost 2022; 48:889.</a></li><li><a class="nounderline abstract_t">Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol 2023; 203:355.</a></li><li class="breakAll">http://www1.wfh.org/publications/files/pdf-1627.pdf (Accessed on June 13, 2017).</li><li><a class="nounderline abstract_t">Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125:553.</a></li><li><a class="nounderline abstract_t">Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73:151.</a></li><li><a class="nounderline abstract_t">Shapiro SE, Phillips E, Manning RA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160:220.</a></li><li><a class="nounderline abstract_t">Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615.</a></li><li><a class="nounderline abstract_t">Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114:249.</a></li><li><a class="nounderline abstract_t">Spena S, Duga S, Asselta R, et al. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites. Blood 2002; 100:4478.</a></li><li><a class="nounderline abstract_t">Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 Suppl 1:125.</a></li><li><a class="nounderline abstract_t">al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46:343.</a></li><li><a class="nounderline abstract_t">Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat 2007; 28:540.</a></li><li><a class="nounderline abstract_t">Casini A, von Mackensen S, Santoro C, et al. Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood 2021; 137:3127.</a></li><li><a class="nounderline abstract_t">Asselta R, Platè M, Robusto M, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost 2015; 113:567.</a></li><li><a class="nounderline abstract_t">Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004; 61:1427.</a></li><li><a class="nounderline abstract_t">Brunclikova M, Simurda T, Zolkova J, et al. Heterogeneity of Genotype-Phenotype in Congenital Hypofibrinogenemia-A Review of Case Reports Associated with Bleeding and Thrombosis. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16:1887.</a></li><li><a class="nounderline abstract_t">Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35:667.</a></li><li><a class="nounderline abstract_t">Ballard JO, Kelly GA, Kukrika MD, et al. Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy. Cancer 1981; 48:686.</a></li><li><a class="nounderline abstract_t">Gralnick HR, Givelber H, Abrams E. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Engl J Med 1978; 299:221.</a></li><li><a class="nounderline abstract_t">Regañón E, Vila V, Aznar J, et al. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 1987; 46:705.</a></li><li><a class="nounderline abstract_t">von Felten A, Straub PW, Frick PG. Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation. N Engl J Med 1969; 280:405.</a></li><li><a class="nounderline abstract_t">Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994; 14:769.</a></li><li><a class="nounderline abstract_t">Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61:1196.</a></li><li><a class="nounderline abstract_t">Martinez J, Keane PM, Gilman PB, Palascak JE. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Ann N Y Acad Sci 1983; 408:388.</a></li><li><a class="nounderline abstract_t">Kwaan HC, Levin M, Sakurai S, et al. Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia. J Vasc Surg 1997; 26:1061.</a></li><li><a class="nounderline abstract_t">Dear A, Brennan SO, Sheat MJ, et al. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain. Haematologica 2007; 92:e111.</a></li><li><a class="nounderline abstract_t">Lee N, Kim JE, Yoo HJ, et al. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency. Ann Clin Lab Sci 2016; 46:696.</a></li><li><a class="nounderline abstract_t">Joshua V, Schobers L, Titcombe PJ, et al. Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells. Arthritis Res Ther 2016; 18:284.</a></li><li><a class="nounderline abstract_t">Liao KP, Sparks JA, Hejblum BP, et al. Phenome-Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis. Arthritis Rheumatol 2017; 69:742.</a></li><li><a class="nounderline abstract_t">Hill JA, Al-Bishri J, Gladman DD, et al. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006; 33:2115.</a></li><li><a class="nounderline abstract_t">Chouhan VD, De La Cadena RA, Nagaswami C, et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77:343.</a></li><li><a class="nounderline abstract_t">Dawson NA, Barr CF, Alving BM. Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985; 78:682.</a></li><li><a class="nounderline abstract_t">Aurousseau MH, Levacher S, Bénéton C, et al. [Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy]. Rev Med Interne 1995; 16:622.</a></li><li><a class="nounderline abstract_t">Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine (Baltimore) 2017; 96:e9124.</a></li><li><a class="nounderline abstract_t">Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer 1971; 27:1313.</a></li><li><a class="nounderline abstract_t">Whitecar JP Jr, Bodey GP, Harris JE, Freireich EJ. L-asparaginase. N Engl J Med 1970; 282:732.</a></li><li><a class="nounderline abstract_t">Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996; 18:105.</a></li><li><a class="nounderline abstract_t">Peng HT, Nascimento B, Rhind SG, et al. Evaluation of trauma-induced coagulopathy in the fibrinogen in the initial resuscitation of severe trauma trial. Transfusion 2021; 61 Suppl 1:S49.</a></li><li><a class="nounderline abstract_t">de Lloyd L, Jenkins PV, Bell SF, et al. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. J Thromb Haemost 2023; 21:862.</a></li><li><a class="nounderline abstract_t">Camilleri RS, Peebles D, Portmann C, et al. -455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications. Blood Coagul Fibrinolysis 2004; 15:139.</a></li><li><a class="nounderline abstract_t">Javorský M, Kozárová M, Salagovic J, Tkáč I. Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients. Physiol Res 2006; 55:55.</a></li><li><a class="nounderline abstract_t">KORST DR, KRATOCHVIL CH. Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. Blood 1955; 10:945.</a></li><li><a class="nounderline abstract_t">Komp DM, Donaldson MH. The relationship between fibrinogen degradation products and cryofibrinogen. Am J Pediatr Hematol Oncol 1979; 1:99.</a></li><li><a class="nounderline abstract_t">Stathakis NE, Karamanolis D, Koukoulis G, Tsianos E. Characterization of cryofibrinogen isolated from patients plasma. Haemostasis 1981; 10:195.</a></li><li><a class="nounderline abstract_t">Tissot JD, Invernizzi F, Schifferli JA, et al. Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples. Electrophoresis 1999; 20:606.</a></li><li><a class="nounderline abstract_t">Lolin Y, Razis PA, O'Gorman P, et al. Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C. J Med Genet 1989; 26:631.</a></li><li><a class="nounderline abstract_t">Wulffraat N, Meyer KJ, Zegers BJ, Kuis W. Familial presence of primary cryofibrinogenaemia, a report of three cases. Br J Rheumatol 1996; 35:102.</a></li><li><a class="nounderline abstract_t">van Geest AJ, van Dooren-Greebe RJ, Andriessen MP, et al. Familial primary cryofibrinogenemia. J Eur Acad Dermatol Venereol 1999; 12:47.</a></li><li><a class="nounderline abstract_t">Paradis C, Cadieux-Dion M, Meloche C, et al. TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia. J Clin Immunol 2019; 39:118.</a></li><li><a class="nounderline abstract_t">Michaud M, Pourrat J. Cryofibrinogenemia. J Clin Rheumatol 2013; 19:142.</a></li><li><a class="nounderline abstract_t">Gómez-Fernández C, López-Sundh AE, González-Vela C, et al. High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreak. Int J Dermatol 2020; 59:1475.</a></li><li><a class="nounderline abstract_t">Blain H, Cacoub P, Musset L, et al. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol 2000; 120:253.</a></li><li><a class="nounderline abstract_t">McKee PK, Kalbfleisch JM, Bird RM. Incidence and significance of cryofibrinogenemia. J Lab Clin Med 1963; 61:203.</a></li><li><a class="nounderline abstract_t">Zlotnick A, Shahin W, Rachmilewitz EA. Studies in cryofibrinogenemia. Acta Haematol 1969; 42:8.</a></li><li><a class="nounderline abstract_t">Smith SB, Arkin C. Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature. Am J Clin Pathol 1972; 58:524.</a></li><li><a class="nounderline abstract_t">RITZMANN SE, LEVIN WC, IVERS JB, KOCH JL. I. CRYOPROTEINEMIAS. 2. PRIMARY CRYOFIBRINOGENEMIA--ITS ASSOCIATION WITH CRYOPATHY AND TELANGIECTASIS. Tex Rep Biol Med 1963; 21:567.</a></li><li><a class="nounderline abstract_t">Rachmilewitz EA, Sacks MI, Zlotnick A. Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr J Med Sci 1970; 6:32.</a></li><li><a class="nounderline abstract_t">Ireland TA, Werner DA, Rietschel RL, et al. Cutaneous lesions in cryofibrinogenemia. J Pediatr 1984; 105:67.</a></li><li><a class="nounderline abstract_t">Crowson AN, Magro CM. Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases. Hum Pathol 1997; 28:478.</a></li><li><a class="nounderline abstract_t">Saadoun D, Elalamy I, Ghillani-Dalbin P, et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122:1128.</a></li><li><a class="nounderline abstract_t">Belizna C, Loufrani L, Subra JF, et al. A 5-year prospective follow-up study in essential cryofibrinogenemia patients. Autoimmun Rev 2011; 10:559.</a></li><li><a class="nounderline abstract_t">Moiseev S, Luqmani R, Novikov P, Shevtsova T. Cryofibrinogenaemia-a neglected disease. Rheumatology (Oxford) 2017; 56:1445.</a></li><li><a class="nounderline abstract_t">McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978; 138:216.</a></li><li><a class="nounderline abstract_t">Tsai RK, Chang CH. Central retinal vein occlusion associated with cryofibrinogenemia in a young adult--study of skin dynamic capillaroscopy. J Formos Med Assoc 1998; 97:777.</a></li><li><a class="nounderline abstract_t">Komp DM, Donaldson MH. In vitro and in vivo effects of heparin on cryofibrinogen. N Engl J Med 1968; 279:1439.</a></li><li><a class="nounderline abstract_t">Stathakis NE, Mosesson MW. Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest 1977; 60:855.</a></li><li><a class="nounderline abstract_t">Hobbs JR. Cryoproteins. Ann Med Interne (Paris) 1986; 137:254.</a></li><li><a class="nounderline abstract_t">Kalivas J. Testing for cryofibrinogenemia. J Dermatol Surg Oncol 1979; 5:361.</a></li><li><a class="nounderline abstract_t">Sankarasubbaiyan S, Scott G, Holley JL. Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am J Kidney Dis 1998; 32:494.</a></li><li><a class="nounderline abstract_t">Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999; 3:8.</a></li><li><a class="nounderline abstract_t">Amdo TD, Welker JA. An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 2004; 116:332.</a></li><li><a class="nounderline abstract_t">Moraru M, Yebra-Bango M, Cisneros E, et al. Cryofibrinogenemia triggered by a monoclonal paraprotein successfully treated with cyclophosphamide. J Clin Rheumatol 2014; 20:34.</a></li><li><a class="nounderline abstract_t">Copeman PW. Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis. Br J Dermatol 1979; 101 Suppl 17:57.</a></li><li><a class="nounderline abstract_t">Siami FS, Siami GA. Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Ther Apher 1997; 1:58.</a></li><li><a class="nounderline abstract_t">Bair JS, Wu YC, Lü YC. Cryofibrinogenemia: report of a case. J Formos Med Assoc 1991; 90:99.</a></li><li><a class="nounderline abstract_t">Young GD, Cleland LG, McNeil JD. Cryofibrinogenaemia: a case report. Aust N Z J Med 1991; 21:444.</a></li><li><a class="nounderline abstract_t">Lazar AP, Lazar P. Giardiasis, cryofibrinogenemia, and cold sensitivity: a response to metronidazole. Int J Dermatol 1991; 30:598.</a></li><li><a class="nounderline abstract_t">Stavem P, Rørvik T, Brandtzaeg P, et al. Gastric lymphoma causing granulocytopenia and cold intolerance, with recovery after treatment. J Intern Med 1991; 229:193.</a></li><li><a class="nounderline abstract_t">Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142:75.</a></li><li><a class="nounderline abstract_t">Jantunen E, Soppi E, Neittaanmäki H, Lahtinen R. Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura. J Intern Med 1993; 234:331.</a></li><li><a class="nounderline abstract_t">Falanga V, Kirsner RS, Eaglstein WH, et al. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Lancet 1991; 338:347.</a></li><li><a class="nounderline abstract_t">Klein AD, Kerdel FA. Purpura and recurrent ulcers on the lower extremities. Essential cryofibrinogenemia. Arch Dermatol 1991; 127:115, 118.</a></li><li><a class="nounderline abstract_t">Kirsner RS, Eaglstein WH, Katz MH, et al. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. J Am Acad Dermatol 1993; 28:71.</a></li><li><a class="nounderline abstract_t">Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995; 33:254.</a></li><li><a class="nounderline abstract_t">Rubegni P, Flori ML, Fimiani M, Andreassi L. A case of cryofibrinogenaemia responsive to stanozolol. Br J Haematol 1996; 93:217.</a></li><li><a class="nounderline abstract_t">Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10:593.</a></li><li><a class="nounderline abstract_t">Khan I, Chow M, Chandra S, Hiatt M. A Case Report of Congenital Afibrinogenemia and Literature Review of Management of Post-circumcision Bleeding. Cureus 2023; 15:e36459.</a></li><li><a class="nounderline abstract_t">Abdelwahab M, de Moerloose P, Casini A. High incidence of intracranial haemorrhage in Egyptian children with congenital afibrinogenaemia. Haemophilia 2023; 29:572.</a></li><li><a class="nounderline abstract_t">Aubrey-Bassler FK, Sowers N. 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review. BMC Emerg Med 2012; 12:11.</a></li><li><a class="nounderline abstract_t">Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4:1634.</a></li><li><a class="nounderline abstract_t">Li Y, Ding B, Wang X, Ding Q. Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review. Thromb Res 2022; 217:36.</a></li><li><a class="nounderline abstract_t">Khayat C, Marchi R, Durual S, et al. Impact of Fibrinogen Infusion on Thrombin Generation and Fibrin Clot Structure in Patients with Inherited Afibrinogenemia. Thromb Haemost 2022; 122:1461.</a></li><li><a class="nounderline abstract_t">Hamano A, Mimuro J, Aoshima M, et al. Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 2004; 103:3045.</a></li><li><a class="nounderline abstract_t">Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44:157.</a></li><li><a class="nounderline abstract_t">Hugon-Rodin J, Carrière C, Claeyssens S, et al. Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study. J Thromb Haemost 2023; 21:2126.</a></li><li><a class="nounderline abstract_t">Benson MD, Liepnieks J, Uemichi T, et al. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet 1993; 3:252.</a></li><li><a class="nounderline abstract_t">Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 1994; 93:731.</a></li><li><a class="nounderline abstract_t">Uemichi T, Liepnieks JJ, Alexander F, Benson MD. The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds. QJM 1996; 89:745.</a></li><li><a class="nounderline abstract_t">Uemichi T, Liepnieks JJ, Yamada T, et al. A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood 1996; 87:4197.</a></li><li><a class="nounderline abstract_t">Uemichi T, Liepnieks JJ, Gertz MA, Benson MD. Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis. Amyloid 1998; 5:188.</a></li><li><a class="nounderline abstract_t">Hamidi Asl L, Liepnieks JJ, Uemichi T, et al. Renal amyloidosis with a frame shift mutation in fibrinogen aalpha-chain gene producing a novel amyloid protein. Blood 1997; 90:4799.</a></li><li><a class="nounderline abstract_t">Hamidi Asl L, Fournier V, Billerey C, et al. Fibrinogen A alpha chain mutation (Arg554 Leu) associated with hereditary renal amyloidosis in a French family. Amyloid 1998; 5:279.</a></li><li><a class="nounderline abstract_t">de Carvalho M, Linke RP, Domingos F, et al. Mutant fibrinogen A-alpha-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid 2004; 11:200.</a></li><li><a class="nounderline abstract_t">Asselta R, Paraboschi EM, Duga S. Hereditary Hypofibrinogenemia with Hepatic Storage. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">van Meegeren ME, de Rooy JW, Schreuder HW, Brons PP. Bone cysts in patients with afibrinogenaemia: a literature review and two new cases. Haemophilia 2014; 20:244.</a></li><li><a class="nounderline abstract_t">Forman WB, Kraus J. Transurethral resection in a patient with a dysfibrinogen: fibrinogen cleveland I. J Urol 1977; 118:885.</a></li><li><a class="nounderline abstract_t">Wada Y, Niwa K, Maekawa H, et al. A new type of congenital dysfibrinogen, fibrinogen Bremen, with an A alpha Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing. Thromb Haemost 1993; 70:397.</a></li><li><a class="nounderline abstract_t">CLAUSS A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17:237.</a></li><li><a class="nounderline abstract_t">Mackie IJ, Kitchen S, Machin SJ, et al. Guidelines on fibrinogen assays. Br J Haematol 2003; 121:396.</a></li><li><a class="nounderline abstract_t">Undas A. How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice? Semin Thromb Hemost 2016; 42:381.</a></li><li class="breakAll">http://practical-haemostasis.com/Screening%20Tests/fibrinogen.html (Accessed on June 16, 2017).</li><li><a class="nounderline abstract_t">Jennings I, Kitchen S, Menegatti M, et al. Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories. Int J Lab Hematol 2017; 39:653.</a></li><li><a class="nounderline abstract_t">Marin MJ, Mathew CM, Rajasekhar A, et al. Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen. Blood Coagul Fibrinolysis 2023; 34:337.</a></li><li><a class="nounderline abstract_t">Casini A, de Moerloose P, Congenital Fibrinogen Disorders Group. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia 2016; 22:898.</a></li><li><a class="nounderline abstract_t">Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167:304.</a></li><li><a class="nounderline abstract_t">Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9:1687.</a></li><li><a class="nounderline abstract_t">Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7:2064.</a></li><li><a class="nounderline abstract_t">Santacroce R, Cappucci F, Pisanelli D, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis 2006; 17:235.</a></li><li><a class="nounderline abstract_t">Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res 2009; 124 Suppl 2:S9.</a></li><li><a class="nounderline abstract_t">Montán C, Johansson F, Hedin U, Wahlgren CM. Preoperative hypofibrinogenemia is associated with increased intraoperative bleeding in ruptured abdominal aortic aneurysms. Thromb Res 2015; 135:443.</a></li><li><a class="nounderline abstract_t">Casini A, de Moerloose P. How I treat dysfibrinogenemia. Blood 2021; 138:2021.</a></li><li class="breakAll">Packaage insert FIBRYGA https://www.fda.gov/media/105864/download (Accessed on June 20, 2023).</li><li class="breakAll">Packaage insert RIASTAP https://www.fda.gov/media/73604/download (Accessed on June 20, 2023).</li><li><a class="nounderline abstract_t">Morrow GB, Feller T, McQuilten Z, et al. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. Crit Care 2022; 26:290.</a></li><li><a class="nounderline abstract_t">Samama CM. Fibrinogen Concentrates for Acquired Fibrinogen Deficiencies? Semin Thromb Hemost 2016; 42:375.</a></li><li><a class="nounderline abstract_t">Rahe-Meyer N, Sørensen B. For: Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011; 9:1.</a></li><li><a class="nounderline abstract_t">Ozier Y, Hunt BJ. Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use. J Thromb Haemost 2011; 9:6.</a></li><li class="breakAll">Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. In: Hematology 2016, Tallman MS, McCrae KR, Smith S, Crowther MA (Eds), American Society of Hematology, Washington, DC 2016. p.663.</li><li><a class="nounderline abstract_t">Bellon A, Fuseau E, Roumanie O, et al. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children. Br J Clin Pharmacol 2020; 86:329.</a></li><li><a class="nounderline abstract_t">Parikh P, Diep K, Balasa V, Lucas TL. Treatment of Congenital Afibrinogenemia in a Neonate With Critical Pulmonary Stenosis. J Pediatr Pharmacol Ther 2023; 28:268.</a></li><li><a class="nounderline abstract_t">Okerberg CK, Williams LA 3rd, Kilgore ML, et al. Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation. Vox Sang 2016; 111:292.</a></li><li><a class="nounderline abstract_t">Cronin C, Fitzpatrick D, Temperley I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol 1988; 79:53.</a></li><li><a class="nounderline abstract_t">MacKinnon HH, Fekete JF. Congenital afibrinogenemia. Vascular changes and multiple thromboses induced by fibrinogen infusions and contraceptive medication. Can Med Assoc J 1971; 104:597.</a></li><li><a class="nounderline abstract_t">DE VRIES A, ROSENBERG T, KOCHWA S, BOSS JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med 1961; 30:486.</a></li><li><a class="nounderline abstract_t">Ménaché D. Congenital fibrinogen abnormalities. Ann N Y Acad Sci 1983; 408:121.</a></li><li><a class="nounderline abstract_t">Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ 1995; 153:147.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Terao T. First report of case of congenital afibrinogenemia with successful delivery. Am J Obstet Gynecol 1985; 153:803.</a></li><li><a class="nounderline abstract_t">Valiton V, Hugon-Rodin J, Fontana P, et al. Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: A systematic literature review. Haemophilia 2019; 25:747.</a></li><li><a class="nounderline abstract_t">Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78:571.</a></li><li><a class="nounderline abstract_t">Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol 1991; 98:722.</a></li><li><a class="nounderline abstract_t">Kobayashi T, Kanayama N, Tokunaga N, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109:364.</a></li><li><a class="nounderline abstract_t">Mensah PK, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia 2011; 17:167.</a></li><li><a class="nounderline abstract_t">Saes JL, Laros-van Gorkom BAP, Coppens M, Schols SEM. Pregnancy outcome in afibrinogenemia: Are we giving enough fibrinogen concentrate? A case series. Res Pract Thromb Haemost 2020; 4:343.</a></li><li><a class="nounderline abstract_t">Pavord S, Rayment R, Madan B, et al. Management of inherited bleeding disorders in pregnancy. Green-top Guideline No. 71. BJOG 2017; 124:e193.</a></li><li><a class="nounderline abstract_t">Cai H, Liang M, Yang J, Zhang X. Congenital hypofibrinogenemia in pregnancy: a report of 11 cases. Blood Coagul Fibrinolysis 2018; 29:155.</a></li><li><a class="nounderline abstract_t">Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis 2009; 20:366.</a></li><li><a class="nounderline abstract_t">Wypasek E, Klukowska A, Zdziarska J, et al. Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations. Thromb Res 2019; 182:133.</a></li></ol></div><div id="topicVersionRevision">Topic 1321 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036059" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations for nomenclature on fibrinogen and fibrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19598064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Congenital fibrinogen disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565160" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235438" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9162058" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Resistance of gammaA/gamma' fibrin clots to fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663453" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14656741" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687509" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The pleiotropic role of the fibrinogen gamma' chain in hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33252741" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fibrinogen and Fibrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17082318" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human plasma fibrinogen is synthesized in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17082318" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human plasma fibrinogen is synthesized in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269818" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822141" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688760" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Control of plasma fibrinogen levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988009" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689082" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Myocardial injury: the acute phase response and lipoprotein metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519751" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : How I use fibrinogen replacement therapy in acquired bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5064500" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/420998" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/796805" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human platelet fibrinogen: a protein different from plasma fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6719392" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma and platelet fibrinogen differ in gamma chain content.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457654" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Unusual A alpha 16Arg--&gt;Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288470" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Congenital dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18272815" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dynamic imaging of fibrin network formation correlated with other measures of polymerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435113" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31011700" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fibrinogen and fibrin: An illustrated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707238" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925485" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12152671" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of gammaA/gamma' fibrinogen levels and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263791" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34183396" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Elimination of fibrinγ-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443961" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dysfibrinogenemia and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1447176" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effect of fibrin structure on fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31011701" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : FibrinogenαC domain: Its importance in physiopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949126" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg--&gt;Cys) in two unrelated kindred, Dusart and Chapel Hill III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558384" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7323804" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fibrinogen and fibrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684777" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A three-dimensional consideration of variant human fibrinogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641664" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The roles of fibrinogen and fibrin in hemostasis and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195697" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27384135" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27019462" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical Features and Management of Congenital Fibrinogen Deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420351" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34958662" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7649481" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141154" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rare inherited disorders of fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23852822" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Congenital fibrinogen disorders: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12754702" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Human Gene Mutation Database (HGMD): 2003 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11460527" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A database for human fibrinogen variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332696" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mutational Epidemiology of Congenital Fibrinogen Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35073585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mutations Accounting for Congenital Fibrinogen Disorders: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37583269" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37583269" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25320241" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Natural history of patients with congenital dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740487" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23061815" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321862" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529842" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The dysfibrinogenaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393540" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635718" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037188" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Congenital afibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17295221" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512441" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427968" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197468" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The molecular mechanisms of congenital hypofibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35207353" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Heterogeneity of Genotype-Phenotype in Congenital Hypofibrinogenemia-A Review of Case Reports Associated with Bleeding and Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076675" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7085917" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acquired dysfibrinogenaemia in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6265056" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/207986" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3629544" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4303132" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7874870" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Coagulopathies of liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6839020" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6575696" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423724" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024387" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27993886" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27906052" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792870" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phenome-Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924693" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9157594" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3985042" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7569436" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : [Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29245350" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5282618" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4906449" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : L-asparaginase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733899" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hematologic manifestations and impaired liver synthetic function during valproate monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34269460" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Evaluation of trauma-induced coagulopathy in the fibrinogen in the initial resuscitation of severe trauma trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36696216" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15091001" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : -455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857159" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13250040" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/543513" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The relationship between fibrinogen degradation products and cryofibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7250786" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Characterization of cryofibrinogen isolated from patients plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10217176" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2585459" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624616" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Familial presence of primary cryofibrinogenaemia, a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10188150" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Familial primary cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685859" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519183" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33070314" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792373" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cryofibrinogenaemia: a study of 49 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Incidence and significance of cryofibrinogenemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4243229" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Studies in cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4642158" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cryofibrinogenemia: incidence, clinical correlations, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14087158" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : I. CRYOPROTEINEMIAS. 2. PRIMARY CRYOFIBRINOGENEMIA--ITS ASSOCIATION WITH CRYOPATHY AND TELANGIECTASIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4097374" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Essential cryofibrinogenemia. Clinical, pathological and immunological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6737150" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cutaneous lesions in cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104949" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Idiopathic perniosis and its mimics: a clinical and histological study of 38 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958891" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cryofibrinogenemia: new insights into clinical and pathogenic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549859" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A 5-year prospective follow-up study in essential cryofibrinogenemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789759" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cryofibrinogenaemia-a neglected disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/626551" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Systemic factors contributory to retinal vein occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872035" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Central retinal vein occlusion associated with cryofibrinogenemia in a young adult--study of skin dynamic capillaroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5722919" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : In vitro and in vivo effects of heparin on cryofibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19499" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767197" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cryoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/457999" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Testing for cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740168" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10079800" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984819" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : An approach to the diagnosis and treatment of cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24356479" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Cryofibrinogenemia triggered by a monoclonal paraprotein successfully treated with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/465341" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Cryofibrinogenaemia and skin ulcers: treatment with plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225783" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1679117" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Cryofibrinogenemia: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1953535" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Cryofibrinogenaemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1938062" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Giardiasis, cryofibrinogenemia, and cold sensitivity: a response to metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997644" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Gastric lymphoma causing granulocytopenia and cold intolerance, with recovery after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415390" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354986" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677702" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986695" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Purpura and recurrent ulcers on the lower extremities. Essential cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425973" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7622653" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Stanozolol as a novel therapeutic agent in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611463" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A case of cryofibrinogenaemia responsive to stanozolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15357789" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36950719" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A Case Report of Congenital Afibrinogenemia and Literature Review of Management of Post-circumcision Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36585888" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : High incidence of intracranial haemorrhage in Egyptian children with congenital afibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889306" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839371" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35853369" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35045578" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Impact of Fibrinogen Infusion on Thrombin Generation and Fibrin Clot Structure in Patients with Inherited Afibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070682" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2652009" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Congenital hypofibrinogenemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37172732" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8097946" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113408" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Hereditary renal amyloidosis with a novel variant fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944230" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639778" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818055" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389696" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Renal amyloidosis with a frame shift mutation in fibrinogen aalpha-chain gene producing a novel amyloid protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10036586" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Fibrinogen A alpha chain mutation (Arg554 Leu) associated with hereditary renal amyloidosis in a French family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523923" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Mutant fibrinogen A-alpha-chain associated with hereditary renal amyloidosis and peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33105716" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Hereditary Hypofibrinogenemia with Hepatic Storage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533951" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Bone cysts in patients with afibrinogenaemia: a literature review and two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/72170" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Transurethral resection in a patient with a dysfibrinogen: fibrinogen cleveland I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259537" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : A new type of congenital dysfibrinogen, fibrinogen Bremen, with an A alpha Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13434757" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : [Rapid physiological coagulation method in determination of fibrinogen].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716361" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Guidelines on fibrinogen assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27071050" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27071050" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28766854" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37395199" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27640400" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Management of congenital quantitative fibrinogen disorders: a Delphi consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100430" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711446" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Fibrinogen replacement therapy for congenital fibrinogen deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19804533" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Pharmacokinetics and safety of fibrinogen concentrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651864" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109654" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455998" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Preoperative hypofibrinogenemia is associated with increased intraoperative bleeding in ruptured abdominal aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895794" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : How I treat dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895794" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : How I treat dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895794" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : How I treat dysfibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36163263" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056153" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Fibrinogen Concentrates for Acquired Fibrinogen Deficiencies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946151" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : For: Fibrinogen concentrate for management of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210948" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210948" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31658379" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37303762" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Treatment of Congenital Afibrinogenemia in a Neonate With Critical Pulmonary Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27248502" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124463" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Multiple pulmonary emboli in a patient with afibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5550548" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Congenital afibrinogenemia. Vascular changes and multiple thromboses induced by fibrinogen infusions and contraceptive medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13720931" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6575680" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Congenital fibrinogen abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7600466" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4073147" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : First report of case of congenital afibrinogenemia with successful delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31368232" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1911348" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883801" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Congenital afibrinogenaemia and successful pregnancy outcome. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10848826" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Prenatal and peripartum management of congenital afibrinogenaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695910" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Congenital afibrinogenaemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32110766" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Pregnancy outcome in afibrinogenemia: Are we giving enough fibrinogen concentrate? A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Management of inherited bleeding disorders in pregnancy. Green-top Guideline No. 71.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29176380" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Congenital hypofibrinogenemia in pregnancy: a report of 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357502" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479941" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
